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Summary 
 
Transposable elements represent nearly half of mammalian genomes and are generally described as parasites or 
‘junk DNA’. The LINE1 retrotransposon is the most abundant class and is thought to be deleterious for cells, yet is 
paradoxically highly expressed during early development. Here we report that LINE1 plays essential roles in mouse 
embryonic stem (ES) cells and pre-implantation embryos. In ES cells, LINE1 acts as a nuclear RNA scaffold that 
recruits Nucleolin and Kap1/Trim28 to repress Dux, the master activator of a transcriptional program specific to the 
2-cell embryo. In parallel, LINE1 RNA mediates binding of Nucleolin and Kap1 to rDNA, promoting rRNA synthesis 
and ES cell self-renewal. In embryos, LINE1 RNA is required for Dux silencing, synthesis of rRNA and exit from the 
2-cell stage. The results reveal an essential partnership between LINE1 RNA, Nucleolin, Kap1 and peri-nucleolar 
chromatin in the regulation of transcription, developmental potency and ES cell self-renewal.  
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Introduction 
 
Only about 1.5% of mammalian genomes is comprised of single-copy protein-coding sequences, whereas 
approximately half of their DNA derives from transposable elements (TEs). Despite their abundance, the roles and 
regulation of TEs have been understudied, in large part due to difficulty in mapping repetitive sequences to the 
genome. Nevertheless, TEs are now accepted as key drivers of genome evolution by rewiring gene regulatory 
networks, including in the human genome (Bourque, 2009).  
 
The retrotransposon Long INterspersed Element 1 (LINE1) makes up the largest proportion of TE-derived sequences, 
and is the only class of autonomous TEs still active in human (Magiorkinis et al., 2015). LINE1-induced mutations 
have been linked to a growing number of diseases, including hematopoietic and neurological disorders, as well as 
several types of cancer [reviewed in (Burns, 2017)]. For this reason, LINE1 is generally thought to be silenced in 
differentiated cell types to avoid uncontrolled mutagenesis. However, the view of TEs such as LINE1 as strictly 
detrimental to cells may be too simplistic. LINE1 is expressed in normal neural progenitor cells, where it has been 
proposed to promote neuronal diversity (Muotri et al., 2005). LINE1 is also expressed in the pre-implantation embryo 
(Fadloun et al., 2013) and in the fetal germline (Ohno et al., 2013, Percharde et al., 2017b). A TE of a different class, 
Mouse Endogenous Retrovirus type L (MERVL), is also expressed in cleavage-stage embryos, where it drives the 
expression of many transcripts specific to zygotic genome activation (ZGA) and totipotency (Kigami et al., 2003, 
Macfarlan et al., 2012, Svoboda et al., 2004). Importantly, the rate of LINE1 retrotransposition in embryos and germ 
cells in vivo is low given the high levels of LINE1 RNA expression (Kano et al., 2009, Richardson et al., 2017, Newkirk 
et al., 2017). These observations raise the possibility that LINE1 RNA has as-yet undefined cellular roles, independent 
of retrotransposition. 
  
We set out to test the hypothesis that LINE1 plays essential functions in mouse pluripotent cells. Our data point to a 
model whereby LINE1 and its chromatin partners are essential to orchestrate developmental progression during pre-
implantation and for the self-renewal of ES cells.  
 
Results  
 
LINE1 RNA is nuclear localized and promotes ES cell self-renewal 
We first set out to investigate the expression and localization of LINE1 in mouse ES cells. LINE1 RNA is detected at 
high levels in a punctate pattern in the nuclei of ES cells, but not in the cytoplasm (Figure 1A), the opposite localization 
pattern of LINE1 protein, Orf1p (Figure S1A). LINE1 RNA is associated with euchromatin and generally excluded 
from heterochromatic foci (Figure 1A). These results are in agreement with the general localization of C0T-I repeat 
RNA, which includes LINE1 RNA (Hall et al., 2014). A similar nuclear localization of LINE1 RNA is detected in mouse 
2-cell embryos and blastocysts [Figure 1B and (Fadloun et al., 2013)]. These results raised the possibility that LINE1 
RNA plays a role in transcriptional regulation in ES cells. 
 
We next developed a LINE1 RNA knockdown (KD) strategy using antisense oligos (ASOs) (Figure 1C). LINE1 ASOs 
lead to a significant reduction in nuclear LINE1 FISH signal, unlike control reverse complement (RC) ASO-treated 
ES cells (Figure 1D-E and S1B). We validated these results using two siRNAs as an independent KD method (Figure 
1C and S1C). The lower level of knockdown using RNAi is to be expected given the greater ability of ASOs to 
knockdown nuclear RNAs (Lennox and Behlke, 2016). Surprisingly, knockdown of LINE1 results in a dramatic 
decrease in ES cell self-renewal (Figure 1F), a result validated by LINE1 RNAi (Figure S1D). In agreement, LINE1 
KD ES cells exhibit a drastically reduced cell expansion rate and an altered cell cycle profile, with a significant 
decrease in the proportion of cells in S phase and an increase in cells in G2/M (Figure S1E-F). This is accompanied 
by only a modest increase in cell death (to ~1% of the total population, Figure S1G), and no changes to the overall 
levels of Oct4 or Nanog proteins (Fig S1H). Taken together, these data indicate that LINE RNA is required for the 
efficient propagation of ES cells.  
 
LINE1 represses the 2C transcriptional program in ES cells 
To analyze the transcriptional impact of LINE1 RNA KD, we performed RNA sequencing (RNA-seq), which revealed 
that LINE1 KD ES cells are reproducibly distinct from controls (Figure 2A and Figure S2A). Genes with a LINE1 
element situated within or nearby show no evidence of downregulation, arguing for a direct effect of KD of LINE1 
RNA itself (Figure S2B). Interestingly, LINE1 KD induces a significant upregulation of 414 transcripts (log2 fold-
change >0.7, FDR <0.05), with only overall mild downregulation of single-copy genes (Figure 2B). Upregulated genes 
do not include markers of the three germ layers (Figure S2C-D), confirming that LINE1 KD does not induce precocious 
differentiation. Instead, there is a striking upregulation of genes transiently expressed at the 2-cell (2C) stage upon 
LINE1 KD (Figure 2C-D, S2E). The 2-cell stage encompasses the switch from maternal control to zygotic genome 
activation (ZGA), and is associated with a sharp, transient upregulation of many genes, termed 2-cell (2C) genes. 
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Several 2C genes contain promoters originally derived from the TE MERVL, which is also sharply induced at this 
stage [reviewed in (Schoorlemmer et al., 2014)]. MERVL and 2C genes are rapidly repressed after the 2-cell stage, 
and in most ES cells (Macfarlan et al., 2011, Wu et al., 2016). 2C genes upregulated upon LINE1 KD include well-
known markers such as Zscan4, Dub1, Gm4340, Tcstv1/3 and Zfp352 (Figure 2E-F and Table S1) along with the 
2C-specific transposon MERVL (Figure 2G-I). 2C gene upregulation was additionally confirmed using LINE1 RNAi 
(Figure S2F). Inhibition of LINE1 retrotransposition using anti-retroviral drugs (Jones et al., 2008) does not phenocopy 
LINE1 RNA KD, indicating that its role in ES cells is independent of retrotransposition (Figure S2G-I). Moreover, 
LINE1 KD does not induce MERVL/2C expression in mouse embryonic fibroblasts (Figure S2J). We examined 
whether LINE1 KD induces conversion of ES cells to a 2C-like fate, using an ES cell line in which endogenous 2C-
like cells are marked by GFP [(Ishiuchi et al., 2015, Macfarlan et al., 2012) and (Figure S2K)]. Depletion of LINE1 
significantly increases the percentage of 2C-like cells that display the expected features:  loss of chromocenters and 
lack of Oct4 protein (Figure 2J-K) or Nanog protein (data not shown). These results indicate that LINE1 acts to repress 
MERVL and the 2C transcriptional program in ES cells. 
 
LINE1 represses Dux, a master activator of the 2C program 
Next, we explored how LINE1 might repress the 2C state in ES cells. LINE1 KD induces a similar phenotype whether 
ES cells are grown in serum/LIF or 2i/LIF conditions [(Ying et al., 2008) and (Figure S3A-B)]. The expression of known 
repressors of the 2C state is not altered in LINE1 KD ES cells (Figure S3C). Interestingly, we found that the 
transcription factor Dux is significantly upregulated upon LINE1 KD (Figure 3A and Table S1). Recently, Dux was 
shown to bind directly to many 2C gene promoters and to be necessary and sufficient for 2C gene upregulation in 
ES cells and for pre-implantation development (De Iaco et al., 2017, Hendrickson et al., 2017, Whiddon et al., 2017). 
Moreover, CRISPR/Cas9-mediated deletion of Dux in zygotes impairs pre-implantation development, suggesting a 
potentially critical role in early development and ZGA (De Iaco et al., 2017). Analysis of RNA-seq data revealed that 
Dux target genes are amongst the most highly activated genes upon LINE1 KD (Figure 3B). Moreover, the repressive 
chromatin mark H3K9me2 is reduced at Dux and its downstream targets in LINE1 KD ES cells (Figure S3D-F). We 
next performed control or LINE1 KD using ASOs, with or without simultaneous KD of Dux using siRNAs (Figure 3C 
and S3G). RNA-seq revealed that Dux depletion significantly reduces the upregulation of Dux targets upon LINE1 
KD (Figure S3H). Moreover, hierarchical clustering of Dux targets revealed that Dux KD rescues the effect of LINE1 
KD (Figure 3D). Similarly, MERVL is no longer upregulated upon simultaneous KD of LINE1 and Dux (Figure 3E-G, 
Figure S3I). These data reveal that the upregulation of the 2C-program in LINE1 KD ES cells is Dux-dependent, 
raising the question of whether LINE1 acts directly or indirectly to restrict Dux expression in ES cells (see below). 
 
LINE1 promotes ES self-renewal independently of its role in repressing Dux 
We subsequently investigated whether the induction of Dux is related to the decrease in self-renewal of LINE1 KD 
ES cells. We found that Dux KD does not rescue the self-renewal deficit observed upon LINE1 KD (Figure 4A), 
indicating that LINE1 plays additional, Dux-independent roles in ES cells. Transcripts upregulated upon LINE1 KD 
include p53 targets (Figure S4A). However, LINE1 KD in p53-/- ES cells (Sabapathy et al., 1997) both activates 2C 
gene expression (Figure S4B) and significantly decreases ES self-renewal (Figure S4C), similarly to wild-type ES 
cells. P53 activation is therefore not a primary cause of the self-renewal deficit of LINE1 KD ES cells.  
  
While down-regulation of single-copy genes is mild in LINE1 KD ES cells (Figure 2B), functional annotations related 
to ribosomal biogenesis and translation are significantly enriched among downregulated genes (Figure 4B, S4D and 
Table S1). Moreover, ribosomal protein genes are reduced in expression upon LINE1 KD (Figure S4E-F) and remain 
downregulated upon simultaneous Dux depletion (Figure 4C and Table S2). Interestingly, ribosomal RNA (rRNA) is 
significantly downregulated upon LINE1 KD (Figure 2H). In agreement, total RNA levels per cell are reduced upon 
LINE1 KD (Figure 4D), along with nascent transcription, rRNA synthesis and nascent translation (Figure 4E-H). Direct 
chemical inhibition of rRNA synthesis (Haddach et al., 2012) leads to a similarly sharp reduction in the self-renewal 
of ES cells (Figure S4G-I). These results suggest that LINE1 promotes high levels of rRNA synthesis typical of and 
required by rapidly growing pluripotent cells (Guzman-Ayala et al., 2015). The self-renewal deficit of LINE1 KD ES 
cells is likely due to a combination of the reduction in nascent transcription, including of rRNA, and the cell cycle 
defects (Figure S1E-F). 
 
LINE1 RNA binds Dux and rDNA loci in ES cells 
We sought to reconcile the seemingly unrelated roles of LINE1 RNA in Dux repression and rRNA synthesis. The high 
abundance of nuclear LINE1 RNA (Figure 1A), as well as previous reports of its close association with chromatin 
(Hall et al., 2014) suggest that it may act similar to nuclear long non-coding RNAs (lncRNAs) to regulate gene 
expression. We therefore performed LINE1 Chromatin Immunoprecipitation by RNA Purification (ChIRP) (Chu et al., 
2011). ChIRP probes designed against the length of L1spa RNA successfully capture LINE1 RNA, but not unrelated 
RNAs (Figure S5A). To assess the specificity of LINE1 RNA ChIRP, we performed parallel Malat1 ChIRP and verified 
its specific association with the Malat1 and Neat1 loci [(Figure S5B) and (Engreitz et al., 2014)]. LINE1 RNA is robustly 
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detected at LINE1 DNA (Figure S5C), as might be expected from the previously reported close association of LINE1 
RNA with chromosome domains from which it is transcribed (Hall et al., 2014). Interestingly, we found that LINE1 is 
significantly enriched at both Dux and rDNA loci compared to Malat1 RNA, but not at control regions (Figure 5A, 
Figure S5B). The LINE1 ChIRP signal is RNA-dependent, as RNase treatment largely prevents the recovery of LINE1 
RNA-bound sites (Figure 5A). The repeated nature of LINE1 and the likelihood that unmapped LINE1 insertions exist 
in the genome may confound the source of the LINE1 ChIRP signal. Nevertheless, these data indicate that LINE1 
RNA interacts with the Dux and rDNA loci, and raise the possibility that it cooperates with factors that regulate 
chromatin activity at these sites.  
  
Nucleolin depletion recapitulates LINE1 knockdown 
Studies in the retrotransposition field have uncovered a number of proteins that interact with LINE1 RNA. One protein 
that caught our attention is Nucleolin, a well-known rDNA and rRNA binding protein required for rRNA synthesis and 
processing (Ginisty et al., 1998). Nucleolin was recovered in a search for proteins that interact with mouse LINE1 
RNA, and this interaction appears to be conserved in human (Moldovan and Moran, 2015, Peddigari et al., 2013). 
Intriguingly, Nucleolin was also reported to bind to and repress the human DUX4 genomic repeat, D4Z4, in HeLa 
cells (Gabellini et al., 2002). Using RNA-immunoprecipitation (RIP)-qPCR, we verified that Nucleolin strongly 
associates, directly or indirectly, with LINE1 RNA in ES cells, at similar levels to pre-rRNA (Figure 5B). The Nucleolin 
RIP-qPCR signal is DNA-independent, indicating that the association of Nucleolin with LINE1 RNA detected by RIP 
is not secondary to binding to DNA (Figure S5D). In contrast, Nucleolin does not bind other RNAs such as the 
spliceosomal-RNA U1 (Figure 5B, S5D), despite its abundant nuclear expression (Figure S5E).  
 
Next, we tested whether Nucleolin may be a repressor of Dux and the 2C program in ES cells. A targeted RNAi 
screen for putative 2C regulators revealed that KD of Nucleolin, but not of several other candidates tested, causes 
dramatic upregulation of Dux, MERVL and 2C genes (Figure 5C and S5F-H). RNA-seq analysis revealed that Dux 
targets and MERVL repeats are among the most highly upregulated transcripts upon Nucleolin KD (Figure 5D-E, S5I 
and Table S3). Moreover, there is a remarkably high similarity between the transcriptomes of ES cells depleted for 
LINE1 or Nucleolin (Figure 5F, Spearman =0.6). These results indicate that Nucleolin KD largely recapitulates 
LINE1 KD at the transcriptional level. Nucleolin knockdown also mimics LINE1 KD ES cells with regards to inducing 
significant decreases in ribosomal protein gene transcription (Figure S5J), total RNA levels (Figure 5G) and ES cell 
self-renewal (Figure 5H). Similarly, Dux KD rescues 2C gene upregulation but not the self-renewal deficit induced by 
Nucleolin KD (Figure S5K-L). Together, our findings indicate that LINE1 RNA and Nucleolin protein interact and have 
overlapping functions in ES cells, including promotion of rRNA synthesis and repression of the Dux/2C program.  
   
Nucleolin and Kap1 bind to Dux and rDNA in a LINE1 RNA-dependent manner  
The only factor to date shown to directly bind and repress Dux in mouse ES cells is the co-repressor tripartite motif-
containing protein 28 (TRIM28/Kap1) (De Iaco et al., 2017). We found that Nucleolin interacts with Kap1 in ES cells, 
suggesting that they may function together in a complex (Figure 6A). Using inducible mutant CreERT2;Kap1fl/fl ES 
cells (Rowe et al., 2010), we confirmed that Kap1 deletion induces a significant increase in Dux and 2C genes and 
MERVL (Figure 6B-C), and that Kap1 or Nucleolin KD both lead to over 10-fold increases in 2C-like cells in vitro 
(Figure 6D). Analysis of published RNA-seq data from Kap1-deleted ES cells (Ecco et al., 2016) also revealed a 
similarity in transcriptional changes to LINE1 KD, albeit less striking than the Nucleolin KD-LINE1 KD similarity (Figure 
S6A, Spearman =0.34 and Figure 5F). We found that both Nucleolin and Kap1 bind Dux loci, and the levels of both 
proteins at Dux are significantly reduced upon LINE1 KD (Figure 6E). Moreover, efficient Nucleolin binding to rDNA 
is also dependent on LINE1 (Figure 6F). Surprisingly, Kap1 is also robustly recruited to rDNA in a LINE1-dependent 
manner (Figure 6F), and Kap1 deletion leads to similar reductions in nascent rRNA transcription as LINE1 or 
Nucleolin KD (Figure S6B). LINE1 KD does not affect the levels of Nucleolin or Kap1 RNA or protein (Figure S3C, 
S6C-E), nor their interaction (Figure S6F). Collectively, these data indicate that LINE1 is essential for the efficient 
chromatin binding of a Nucleolin-Kap1 complex that represses Dux and promotes rRNA expression. 
 
Subsequently we sought to interrogate what might be different in 2C-like cells, compared to standard ES cells, that 
allows for induction of Dux and the 2C program. While the levels or localization of Kap1 and Nucleolin are unchanged 
(Figure S6G), the nuclear abundance of LINE1 RNA is significantly reduced in 2C-like cells compared to ES cells 
(Figure 6G). In addition, 2C-like cells have significantly fewer nucleoli per cell compared to ES cells (Figure S6H). 
DNA FISH revealed that in ES cells the Dux loci are most often located in the peri-nucleolar or laminar regions (Figure 
6H, S6I-K), both of which are thought to be transcriptionally repressive heterochromatin environments (Guetg and 
Santoro, 2012, Reddy et al., 2008). Intriguingly, the transition of ES cells to the 2C-like state is accompanied by a 
release of Dux loci from the Nucleolin-positive domain at peri-nuclelolar regions to the nucleoplasm (Figure 6H, S6K). 
Taken together, these data suggest that a combination of reduced abundance of LINE1 RNA with changes to the 
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interaction of Dux with Nucleolin at peri-nucleolar heterochromatin may facilitate the entry of ES cells into a 2C-like 
state, a possibility that deserves future exploration. 
 
LINE1 promotes silencing of the Dux/2-cell program, rRNA synthesis and developmental progression past 
the 2-cell stage 
Lastly, we investigated the role of LINE1 in embryonic development (Figure 7A). Almost no LINE1 KD embryos reach 
the blastocyst stage and most arrest at the 2-cell stage (Figure 7B and S7A). Furthermore, 2-cell LINE1 KD embryos 
display high upregulation of Dux as well as its target 2-cell gene, Zscan4 (Figure 7C). In contrast, the expression of 
Eif1a, a marker of ZGA (Davis et al., 1996, Zeng and Schultz, 2005), is sharply reduced upon LINE1 KD. 2-cell 
embryos depleted of LINE1 exhibit significant reductions in chromatin accessibility (Figure S7B) in agreement with 
(Jachowicz et al., 2017), and display significantly increased levels of heterochromatin (Figure S7C). While control 
ASO-injected embryos show the expected strong cytoplasmic accumulation of 18S rRNA, in LINE1 ASO-injected 
embryos 18S rRNA is largely retained in the nucleus (Figure 7D). In agreement, chemical inhibition of rRNA synthesis 
from either the zygote (Lin et al., 2014) or 2-cell stage onwards (Figure S7D) is incompatible with pre-implantation 
development.  
 
We next performed RNA-seq on samples where zygotes were microinjected with lower concentrations (0.5X) of ASOs 
to allow some LINE1 KD embryos to progress to the 4-cell stage (Figure 7E). Very few transcriptional changes are 
detected in LINE1 KD embryos at the early 2-cell stage. In contrast, LINE1 KD 4-cell embryos are transcriptionally 
distinct from controls (Figure S7E, and Table S4). Using published data (Wu et al., 2016), we defined gene clusters 
associated with Dux/early 2-cell gene expression (cluster 4, Figure 7F and S7F), or with elevated expression 
maintained up to the 4-cell stage (cluster 1, Figure 7F and S7F). 4-cell LINE1 KD embryos display a significant 
upregulation of early 2-cell genes and reduced expression of 4-cell genes (Figures 7G-H and S7G). Genes associated 
with ZGA (Zeng and Schultz, 2005) are significantly decreased in 4-cell LINE1 KD embryos (Figure 7F-G), along with 
ribosomal genes (Figure S7H).  
 
Finally, we performed LINE1 KD at the late 2-cell stage, when Dux has already been silenced and ZGA initiated 
(Figure 7I). Very few of these LINE1 KD embryos develop past the 4-cell stage (Figure 7J and Figure S7I). Moreover, 
4-cell embryos depleted of LINE1 from the late 2-cell stage display upregulation of MERVL and 2-cell genes (Figure 
7K and S7J). Overall, these data indicate that there is an ongoing requirement for LINE1 RNA for repression of the 
2-cell program and developmental progression during early embryogenesis. Taken together, the data suggest that a 
failure to repress the Dux/2-cell program and defective ZGA and ribogenesis contribute to embryonic arrest upon 
LINE1 depletion.  
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Discussion  
 
The expression of TEs such as LINE1 is generally thought to be detrimental to cells because it can cause mutations 
or apoptosis [e.g. (Malki et al., 2014, Burns, 2017)]. In contrast, we report here that the expression of LINE1 regulates 
exit from the 2-cell state by performing two main functions: repressing the 2C program induced by Dux, and activating 
rRNA synthesis to support rapid proliferation. These two functions are unified by the interaction of LINE1 RNA with 
Nucleolin, which we identify as a novel repressor of the Dux/2C program. Thus, rather than being a simple genomic 
parasite, LINE1 may best be viewed as a symbiont that is an integral part of the transcriptional networks that regulate 
cellular potency during early mammalian development (Figure 7L). 
 
Nucleolin is most commonly associated with the positive regulation of rRNA synthesis (Ginisty et al., 1998). In recent 
years, Nucleolin has been shown to also have roles in chromatin remodeling, DNA replication, and DNA repair 
[reviewed in (Jia et al., 2017)]. Our work uncovers a novel function for Nucleolin, and it will be of interest to identify 
the functional elements in the LINE1 RNA by defining the regions that interact with Nucleolin and potentially other 
factors, like Kap1. Intriguingly, the region of mouse LINE1 RNA previously used to identify Nucleolin as an interactor 
was the interORF (Peddigari et al., 2013), the same region against which we designed the LINE1 ASO (Fig. 1C). It 
is therefore possible that the ASO disrupts the interaction between LINE1 RNA and Nucleolin, which in turn may 
contribute to destabilizing LINE1 RNA.   
  
It remains unclear how LINE1 RNA-Nucleolin-Kap1 are targeted to the Dux cluster. LINE1-Nucleolin-Kap1 may have 
other interacting partners with DNA binding specificity. For example, YY1 has been implicated in targeting a 
repressive complex containing Nucleolin to the human DUX4 cluster (Gabellini et al., 2002), although we did not find 
a role for YY1 in Dux repression in ES cells (Figure 5C). Alternatively, KRAB-ZFP transcription factors are known to 
recruit Kap1 to repress TEs (Lupo et al., 2013, Wolf et al., 2015), a function that might have been coopted for Dux 
silencing. Finally, our data leave open the possibility that transcribed LINE1 DNA loci contribute in cis to Dux 
repression or rRNA activation via higher-order chromosome interactions (Figure 7L). Furthermore, while LINE1 is 
specifically detected at Dux and rRNA, it is likely to have other genomic targets that remain to be discovered.  
 
Our data suggest that the LINE1-Nucleolin-Kap1 complex has both an activating function (at rDNA) and a repressive 
function (at Dux). While this might seem paradoxical, Nucleolin and Kap1 have been shown to have both activating 
and repressive effects. In addition to its role as activator of rDNA, Nucleolin has been reported to repress the 
expression of genes such as cMyc (Gonzalez et al., 2009), MMP13 (Samuel et al., 2008) or the D4Z4 repeat (Gabellini 
et al., 2002). Conversely, the co-repressor Kap1 also has activating functions both at the single gene level (Singh et 
al., 2015), as well as globally (Bunch et al., 2014). It is possible that the reduction in nascent rRNA synthesis in Kap1 
mutant ES cells contributes their self-renewal defect, in addition to the previously reported de-repression of 
endogenous retroviruses (Rowe et al., 2010). Moreover, the localization of Dux loci to Nucleolin-positive peri-
nucleolar regions in ES cells but not 2C-like cells provides a potential rationale at the level of nuclear 3D organization 
for the coordinate roles of LINE1/Nucleolin/Kap1 in activation of rDNA vs repression of Dux. 
 
LINE1 is expressed throughout pre-implantation development (Figure 1B and (Fadloun et al., 2013)), which implies 
that its presence alone may not suffice to repress Dux and the 2C program. However, analysis of RNA-seq data from 
early embryos reveals that Nucleolin and Kap1 are sharply induced at the late 2-cell stage, correlating with Dux 
silencing (Figure S7K). Thus, it is possible that, by promoting ZGA at the 2-cell stage, Dux induces several of its own 
repressors, which can then bind LINE1 RNA and silence the Dux loci. Moreover, there are large-scale changes to 
the organization of the nucleolus and its associated heterochromatin during these stages (Borsos and Torres-Padilla, 
2016) that may pertain to the silencing of the Dux/2C program. 
 
It has been proposed that the retrotransposition activity of LINE1 is essential for early mouse development, possibly 
by making cDNA copies of sperm-derived RNAs (Beraldi et al., 2006, Sciamanna et al., 2009). Using inhibitors that 
block LINE1 mobility [Figure S2G and (Jones et al., 2008)], we found that retrotransposition is not involved in the 
regulation of 2C gene expression nor of ES cell self-renewal (Figure S2H-I). Moreover, LINE1 ORF1 protein, which 
is required for retrotransposition, is predominantly cytoplasmic (Figure S1A), in contrast to the nuclear localization of 
LINE1 RNA. While we cannot at present exclude a non-canonical function for LINE1 ORF1 or ORF2 proteins in the 
developmental roles reported here, our data indicate that it acts as a chromatin-associated RNA that binds Nucleolin 
and Kap1 to regulate gene expression. 
  
The partnership between LINE1 and Nucleolin in the regulation of rRNA synthesis indicates that LINE1 contributes 
to ES cell hypertranscription (Percharde et al., 2017a). This notion is supported by the fact that LINE1 KD leads to 
decrease in total RNA levels, nascent transcription, nascent translation and self-renewal. Although we do not detect 
LINE1 RNA binding at ribosomal protein genes, the synthesis of rRNA and ribosomal proteins genes is highly 
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coordinated (Laferte et al., 2006). In addition, we have recently shown that reductions in translational output in ES 
cells rapidly induce a decrease in nascent transcription of highly-expressed genes, including rRNA and ribosomal 
protein genes (Bulut-Karslioglu et al., 2018). Our data support a model whereby LINE1-mediated induction of rRNA 
synthesis leads to global increases in ribosomal biogenesis, enabling rapid growth of the early embryo. We speculate 
that the LINE1-Nucleolin partnership may play roles in other stem/progenitor cells, where it might not necessarily act 
to repress Dux but may still promote ribogenesis and proliferation. 
 
Our work raises the question of how a mechanism for control of developmental potency based on TEs might have 
evolved. Active TEs are under acute surveillance by cellular pathways that minimize transposition, including by Kap1 
(Rowe et al., 2010). In part because of this, and in part because of a loss in ability to transpose due to an accumulation 
of mutations, the sequence of TEs is generally thought to be subject to a rapid rate of divergence. In fact, some 
mammalian species may have completely lost all retrotransposition-competent LINE1 elements in their genome, even 
though they can still express mutated LINE1 RNAs (Cantrell et al., 2008). Our results indicate that chromatin-
associated LINE1 RNA regulates gene expression and developmental potency without requiring retrotransposition 
activity. This role of LINE1 as a chromatin-associated RNA therefore avoids the potential detrimental effects of LINE1 
retrotransposition that have been reported in several disease states, including cancer (Burns, 2017). The interaction 
of LINE1 RNA with binding partners such as Nucleolin is expected to be mediated by RNA secondary structure, which 
is less constrained by primary sequence than protein-coding regions. Thus, rather than being a vulnerability, the 
regulation of early development by TEs may allow both robustness, due to the repeated nature of TEs, and 
adaptability, due to their rapid evolution and their potential to support transposition in conditions of stress. In this 
regard, it is interesting that the percentage of the genome occupied by LINE1 elements seems to have sharply 
increased with development of therian mammals [e.g., (Ivancevic et al., 2017)]. The exploration of the function of 
LINE1 in other species should shed light on the role of TEs in shaping the evolution of development. 
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Figure Legends 
 
Figure 1. LINE1 RNA is nuclear localized in ES cells and is essential for self-renewal.  
(A) LINE1 RNA FISH in ES cells, in the indicated conditions. Scale bar, 10m.  
(B) LINE1 RNA FISH in mouse 2-cell embryos and blastocysts. Scale bar, 20m.  
(C) Schematic of full-length LINE1 mRNA indicating the positions of the inter-ORF LINE1 ASO and the two 
independent siRNA sequences used in this study. The reverse complement (RC) of the LINE1 ASO is used 
throughout as a negative control.  
(D) Workflow of LINE1 experiments. 
(E) RNA FISH in ES cells showing nuclear LINE1 depletion 48h following nucleofection with LINE1 ASO. LINE1 RNA 
foci per cell were quantified in each condition from multiple fields, with mean +/- s.d indicated. Scale bar, 10m.  
(F) Representative images and quantification of the number of AP-positive colonies 5-6 days after initial plating. Data 
are mean +/- s.e.m., n=3 biological replicates. See also Figure S1. 
 
Figure 2. LINE1 knockdown causes upregulation of 2C genes and MERVL.  
(A) PCA plot for all genes across all samples, showing that LINE1 KD ES cells have distinct gene expression profiles 
and are separated from controls along PC1.  
(B) MA plot showing log2 fold-changes in the expression of each gene following LINE1 KD. Horizontal red or blue 
lines indicate FDR <0.05 and log2 fold-chance (FC) of > 0.7 or < -0.7, respectively. Select upregulated 2-cell (2C) 
genes are labeled in black.  
(C) Heatmap showing expression changes of 142 2C genes as defined in (Macfarlan et al., 2012), upon LINE1 KD.  
(D) GSEA for 2C genes as in (C) showing a preferential upregulation of nearly all genes upon LINE1 KD.  
(E) Browser RNA-seq screenshots of 2C genes Zscan4d and Dub1 in RC or LINE1 ASO samples.  
(F) qRT-PCR validation of 2C gene upregulation following LINE1 KD with ASOs. Data are mean +/- s.e.m., n=3 
biological replicates.  
(G). Distance analysis performed on the indicated sets of genes, calculating of log2 absolute distance in base-pairs 
(bp) to the nearest MERVL element. 2C/ASO intersect: 52 2C genes from (Macfarlan et al., 2012) also significantly 
upregulated with LINE KD; ASO upregulated: all significantly upregulated genes upon LINE1 KD. **P < 0.01, two-
sided Wilcoxon rank sum test, calculated between 2C/ASO intersect and all expressed genes.  
(H) MA plot showing log2 fold-changes in repeat expression following LINE1 KD. Upregulated MERVL repeats, and 
downregulated rRNA repeats, are indicated.  
(I) qRT-PCR validation of MERVL expression following LINE1 KD. Data are mean +/- s.e.m., n=3 biological replicates.  
(J) Percentage of 2C-like cells and representative micrographs in 2C-GFP reporter ES cells 48h after nucleofection 
with ASOs. Data are mean +/- s.e.m of 2 independent experiments. 
(K) Immunofluorescence analysis of LINE1 KD-induced 2C-like cells. Graph depicts the percentage of GFP+ cells 
that have the expected features (loss of chromocenters and Oct4 protein). Scale bar, 10m, n=number of cells. See 
also Figure S2 and Table S1. 
 
Figure 3. The activation of the 2C program induced by LINE1 knockdown is Dux-dependent.  
(A) qRT-PCR showing Dux upregulation with LINE1 KD. Data are mean +/- s.e.m., n=4 biological replicates.  
(B) Boxplot analysis of significantly altered genes (FDR <0.05) upon LINE1 KD, showing that Dux targets are 
significantly more induced than non-targets. P-value is determined by two-sided Wilcoxon rank sum test.  
(C) Workflow of LINE1/Dux knockdown experiments.  
(D) Heatmap showing suppression of induction of Dux and top Dux target genes, defined as in (B), in LINE1 KD cells 
upon simultaneous Dux KD. 
(E-F) MA plots of repeat expression changes in LINE1 vs RC ASO treatment, either with transfection of (E) siControl 
or (F) siDux.  
(G) qRT-PCR validation of 2C gene and MERVL rescue following Dux depletion. Data are representative of 3 
independent experiments, shown is mean +/- s.e.m., n=3 technical replicates. See also Figure S3 and Table S2. 
 
Figure 4. LINE1 promotes translation and ES self-renewal independently of Dux.  
(A) Colony-formation assay showing that Dux knockdown does not rescue self-renewal upon LINE1 KD. Data are 
mean +/- s.e.m., n=3 biological replicates.  
(B-C) GSEA plot showing preferential downregulation of the KEGG ribosome pathway following LINE1 KD, with either 
co-transfection of (B) Control or (C) Dux siRNAs.  
(D) RNA per cell in ES cells 48h after nucleofection with RC or LINE1 ASOs. Data are mean +/- s.e.m., n=6 
independent batches of equal numbers of cells.  
(E) Diagram of experiments labelling nascent RNA/proteins with EU/HPG following ASO nucleofection.  
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(F) Representative histogram (left) of nascent transcription in RC or LINE1 ASO-treated samples 24-48h after 
nucleofection, with cells incubated without EU shown as control, and quantification (right) showing the relative 
decrease in translation upon LINE1 KD. Data are = mean +/- s.e.m., n=2 independent experiments. 
(G) qRT-PCR showing decrease in rRNA and ribosomal protein gene expression 48h after LINE1 KD, shown as 
mean +/- s.e.m, n=3 biological replicates. 
(H) Representative histogram (left) and quantification (right) as in (G), but performed for HPG incubations 48h after 
LINE1 KD. Data are = mean +/- s.e.m., n=4 independent experiments. See also Figure S4. 
 
Figure 5.  LINE1 RNA interacts with Nucleolin to coordinately repress Dux and activate rRNA synthesis. 
(A) ChIRP enrichment in wild-type ES cells at the indicated DNA loci, using biotinylated probes against LINE1 RNA. 
Intergenic-chromosome 11 (int-chr11) and Rpl3-TSS are shown as negative regions. Data are mean +/- s.e.m., n=3 
independent experiments.  
(B) RIP in wild-type ES cells with Nucleolin (Ncl) or control IgG antibodies, showing Ncl association with the indicated 
RNAs. Pre-rRNA is shown as a positive control. Data are mean +/- s.e.m., n=2 independent experiments, and shown 
as % input normalized to Malat1 RNA.  
(C) qRT-PCR showing knockdown of candidate 2C/Dux repressors alongside Dux and 2C gene expression. Data are 
representative of two independent experiments and are mean +/- s.e.m., n=3 technical replicates.  
(D) PCA plot for all genes across all samples, showing that Ncl KD ES cells have distinct gene expression profiles 
and are separated from controls along PC1.  
(E) Boxplot analysis of significantly altered genes (FDR <0.05) upon Ncl knockdown, revealing that Dux targets are 
significantly more induced than non-targets (see Fig. 3B). P-value is determined by two-sided Wilcoxon rank sum 
test.  
(F) Scatter plot showing the log2 fold-change (FC) in the expression of all genes following LINE1 KD (x axis) or Ncl 
KD (y axis). Dux targets are indicated in red, with select 2C genes labelled in black. The Spearman’s correlation 
coefficient is indicated. 
(G) RNA per cell in ES cells 48h after transfection with control or Ncl siRNAs. Data are mean +/- s.e.m., n=4 
independent batches of equal numbers of cells.  
(H) Colony-formation assay in ES cells following transfection with control or Ncl siRNAs. Data are mean +/- s.e.m., 
n=3 biological replicates. See also Figure S5 and Table S3. 
 
Figure 6. LINE1 promotes binding of Nucleolin and Kap1 to Dux and rDNA. 
(A) Co-IP showing association of endogenous Kap1 and Ncl proteins in ES cells.  
(B-C) qRT-PCR confirming (B) Kap1 deletion and (C) upregulation of Dux, 2C genes, and ERVs. Data are mean +/- 
s.e.m, n=3 biological replicates. 
(D) Representative micrographs (left) and percentage of 2C-like cells (right) in 2C-GFP reporter ES cells 3 days 
following siRNA KD of Ncl or Kap1, in n=2 independent experiments. 
(E-F) ChIP assays for Ncl and Kap1 at (E) Dux and (F) rDNA, with or without LINE1 KD. Data are shown as % input 
normalized to enrichment at int-chr11 negative control region, and are mean +/- s.e.m., n=3 independent experiments 
for Ncl ChIP, and n=2 independent experiments, Kap1 ChIP.  
(G) Example images and quantification of nuclear LINE1 RNA foci by RNA-FISH in ES cells (2C-GFP-) or 2C-like 
cells (2C-GFP+), representative of 2 experiments. Scale bar, 10m, n=number of cells. 
(H) Representative images and quantification of distinct localization patterns of Dux loci in ES vs 2C-like cells by IF 
for Ncl combined with Dux DNA-FISH, using 2C-GFP reporter ES cells. Nucleoli are labeled with Ncl antibodies. 
Example Dux loci are indicated (white arrows), showing two nucleolar loci in an ES cell vs one nucleoplasmic locus 
in a 2C-like cell. Statistics are calculated by Chi-squared test for the indicated number (n) of Dux loci. Scale bar, 2m. 
See also Figure S6. 
 
Figure 7. LINE1 regulates Dux silencing, rRNA synthesis and early development.  
(A) Summary diagram of ASO microinjection experiments in panels (B-D).  
(B) Developmental progression in the indicated number (n) of embryos following ASO microinjections, collected in 3 
independent experiments. χ2 P-values were calculated for the developmental rate of embryos injected with LINE1 or 
Control ASOs.  
(C) qRT-PCR for the indicated genes in late 2-cell (2C) embryos harvested 24h post injection. Data are mean +/- 
s.e.m., n=3 technical replicates, showing 2 independent experiments. 
(D) 18S RNA FISH in late 2C embryos 24h following microinjection with Control or LINE1 ASOs, with nuclei stained 
by DAPI. Nuclear or cytoplasmic foci were counted in each embryo and plotted below as 18S cytoplasmic/nuclear 
ratio. Data show mean +/- s.d from the indicated number (n) of embryos from 2 independent experiments. Scale bar, 
20m. 
(E) Summary diagram of 0.5X ASO microinjection experiments for RNA-seq in panels (F-H).  
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(F) RNA-seq data from (Wu et al., 2016), showing mean FPKM expression relative to MII oocyte for the indicated 
gene sets identified by K-means clustering, or for ZGA genes defined in (Zeng and Schultz, 2005). Shading denotes 
mean +/- s.e.m at each time point. 
(G) Boxplot depicting the log2-fold change in 4-cell (4C) embryos upon LINE1 KD for the indicated number (n) of gene 
sets displayed in (G), compared to all expressed genes. P-value, two-sided Wilcoxon rank sum test. 
(H) Examples of the expression of early 2C genes, Dux and Zscan4d, in the indicated embryo samples. P-value, 
toptable FDR, showing n=3 samples per condition. 
(I) Summary diagram of late 2C ASO microinjection experiments in panels (J-K).  
(J) Developmental progression in the indicated embryos following late 2C ASO microinjections. χ2 P-values were 
calculated for the developmental rate of the number (n) of embryos injected with 1X RC or LINE1 ASOs. 
(K) qRT-PCR analysis of MERVL expression in 4C or 5-8C embryos following late 2C microinjections with ASOs. 
Data are mean +/- s.e.m n=3 technical replicates and are representative of 3 (LINE1 ASO) or 2 (RC ASO) 
independent experiments. 
(L) Model for the role of LINE1 in early development and ES cells. LINE1 acts as an RNA-scaffold and binds to rDNA 
and Dux. LINE1 RNA-Ncl-Kap1 cooperate to turn off the 2C gene expression program and promote high levels of 
ribosome biosynthesis during early development. See also Figure S7 and Table S4. 
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Supplemental Figure Legends 
 
Figure S1, related to Figure 1. Knockdown of LINE1 RNA by siRNAs.  
(A) Representative immunofluorescence staining showing cytoplasmic LINE1 Orf1p in ES cells. Scale bar, 10m. 
(B) Representative FACS plots showing percentage Lissamine-positive ES cells 48h after nucleofection with 
Lissaminated RC or LINE1 ASOs  
(C) Representative images and quantification of LINE1 RNA FISH in ES cells 48h after transfection with either Control 
or two independent siRNAs against LINE1. Data are mean +/- s.d for the indicated number (n) of cells.  Scale bar, 
10m. 
(D) Colony formation assays in ES cells following transfection with control (RC) or LINE1 siRNAs. Data are mean +/- 
s.e.m, n =3 biological replicates.  
(E) Growth curves of ES cells following nucleofection with RC or LINE1 ASOs, shown as mean +/- s.e.m, n=3 
biological replicates.  
(F) Cell-cycle analysis 48h after RC/LINE1 ASO nucleofection, with representative FACS plots and quantification of 
n=3 biological replicates. **P < 0.01, Chi-squared test. 
(G) Cell viability analysis in Lissamine-positive ES cells, measured by Sytox-blue staining. Dead cells (permeabilized 
with 4% paraformaldehyde for 30 min) were used as a positive control for Sytox-blue staining. Shown are 
representative FACS plots plus quantification from n=3 independent experiments, +/- s.e.m. 
(H) Western blot (left) and immunofluorescence (right) analysis showing no overall change to Oct4/Nanog protein 
levels in ES cells 48h after LINE1 KD. Scale, 10m. 
 
Figure S2, related to Figure 2. Induction of a 2C-like state upon LINE1 knockdown.  
(A) LINE1 KD ES cells show a distinct gene expression profile, as evidenced by unsupervised hierarchical clustering 
of samples using Pearson Correlation coefficients.  
(B) Boxplot showing log2FC in LINE1- vs RC ASO-nucleofected samples of the indicated number (n) of genes. Note 
that categories are non-inclusive, i.e., L1 <100kb refers to genes <100kb but >10kb away from a full-length LINE1 
element. P values are calculated by two-sided Wilcoxon rank sum test. 
(C) Expression analysis of pluripotency genes and markers from all 3 germ layers, taken from RNA-seq data following 
LINE1 KD. Data are mean +/- s.e.m, n=3 biological replicates in each condition. Endo, endoderm, Meso, mesoderm, 
Ecto, ectoderm, plurip, pluripotency. 
(D) qRT-PCR validation of germ layer marker expression following ASO treatment. Data are mean +/- s.e.m, n=4 
biological replicates  
(E) Venn diagrams indicating the overlap between top upregulated genes with LINE1 KD (log2 fold-change > 1.0) and 
the indicated datasets. Datasets are as follows, ‘Up in 2C-like cells’: significantly upregulated genes in 2C-tdTomato+ 
cells (log2 fold-change > 1.0), ‘Up with CAF-1 depletion’: overlap of top 200 genes upregulated upon knockdown of 
both subunits of CAF-1 [(p60, p150), (Ishiuchi et al., 2015)], ‘Up in Zscan4+/MERVL+ cells’: genes upregulated in 
Zscan4/MERVL-double-positive cells [(log2 fold-change > 1.0), (Eckersley-Maslin et al., 2016)]. P-values were 
calculated by Fisher’s exact test, assuming a universe of 18,000 expressed genes.  
(F) 2C gene expression 48h after transfection of ES cells with Control or LINE1 siRNAs. Data are mean +/- s.e.m, 
n=3 biological replicates.  
(G) LINE1 retrotransposition assay, where retrotransposition mediated by a codon-optimized LINE1 transgene 
(ORFeus) (An et al., 2006, Newkirk et al., 2017) results in GFP expression. Treatment with LINE1 reverse 
transcriptase inhibitors, Stavudine (d4T, 20M) or Tenofovir disoproxil fumarate (TDF, 4M) inhibits LINE1 
retrotransposition. Data are number of GFP-positive cells per 300,000 live cells, representative of 2 independent 
experiments.  
(H) Colony formation assay of ES cells treated with reverse transcriptase inhibitors, indicating that inhibition of LINE1 
retrotransposition does not affect self-renewal. Data are mean +/- s.e.m, n=4 biological replicates. (I) 2C gene 
expression after 48h treatment with reverse transcriptase inhibitors, data are mean +/- s.d, n=2 biological replicates 
(J) Expression of 2C genes or TEs 48h after LINE1 KD in MEF cells. Data are mean +/- s.e.m, n=3 biological 
replicates.  
(K) Validation of clonal 2C-GFP reporter ES cells, by qRT-PCR analysis performed for Dux and 2C genes in sorted 
2C-GFP positive vs negative cells. Data are mean +/- s.d n=2 biological replicates. n.s., not significant, n.d., not 
detected.  
 
Figure S3, related to Figure 3. Dux knockdown rescues 2C/MERVL upregulation induced by LINE1 
knockdown.  
(A) qRT-PCR analysis showing Dux and 2C upregulation in ES cells cultured in N2B27/2i/LIF conditions upon LINE1 
KD. Data are mean +/- s.e.m, n=3 technical replicates, representative of 3 experiments. 
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(B) Colony formation assay performed in nucleofected ES cells cultured in N2B27/2i/LIF conditions. Data are mean 
+/- s.e.m, n=3 biological replicates.  
(C) Expression analysis of previously reported 2C/MERVL repressors following LINE1 KD, taken from RNA-seq data. 
Data are mean +/- s.e.m, n=3 biological replicates in each condition. 
(D-F) ChIP assays for the histone marks (D) H3K9me2, (E) H3K9me3, or (F) H3K27me3 performed 48h after 
nucleofection with ASOs and sorting for Lissamine+ cells. Data are mean +/- s.e.m n=2 technical replicates, 
representative of at least 2 independent experiments.  
(G) Principal Component Analysis (PCA) plot for all genes across all samples, confirming ASO/siRNA RNA-seq 
samples have distinct gene expression profiles.  
(H) Boxplot analysis of Dux-target genes following LINE1 KD and co-transfection of either siControl or siDux (n=100 
genes expressed in our data, from the original list of 200 most-upregulated genes). P-value is determined by two-
sided Wilcoxon rank sum test.  
(I) Graph of MERVL repeat expression in RNA-seq samples, showing that simultaneous Dux knockdown rescues 
MERVL upregulation upon LINE1 KD.  
 
Figure S4, related to Figure 4. Effects of LINE1 knockdown are not p53-mediated and include reductions in 
ribosomal protein gene expression.  
(A) GSEA analysis of RNA-seq data in LINE1 vs RC nucleofected ES cells, showing a preferential upregulation of 
p53 targets upon LINE1 KD.  
(B) qRT-PCR analysis of 2C/MERVL gene expression in p53-/- ES cells analyzed 24-48h after nucleofection with 
RC/LINE1 A18SOs. Data are mean +/- s.e.m, n=3 biological replicates, normalized to RC ASO 24h. #P <0.01, LINE1 
ASO 24h vs RC ASO 48h. 
(C) Colony formation assay in p53-/- ES cells, showing that LINE1 KD still inhibits self-renewal. Data are mean +/- 
s.e.m, n=3 biological replicates.  
(D) GSEA analysis as in (A), demonstrating a preferential downregulation of ribosomal genes upon LINE1 KD.  
(E) Heatmap analysis of n=86 ribosomal genes in RC or LINE1 ASO RNA-seq samples, with samples grouped by 
unsupervised hierarchical clustering. 
(F) Boxplot depicting downregulation of Rpl/Rps genes compared to all expressed genes upon LINE1 KD. P-value 
calculated by two-sided Wilcoxon rank sum test.  
(G) Nascent RNA expression of the indicated ribosomal RNA and protein-coding genes following 8h treatment with 
CX-5461. Data are mean +/- s.e.m, n=2 biological replicates. 
(H) Colony formation assay performed in ES cells plated after 8 h treatment with CX-5461. Data are mean +/- s.e.m, 
n=3 biological replicates. 
(I) Growth curves of ES cells with or without 8h CX-5461 treatment. Data are mean +/- s.e.m, n=3 biological replicates.  
 
Figure S5, related to Figure 5. LINE1 and Nucleolin repress Dux and the 2C/MERVL program. 
(A) Analysis of the amounts of the indicated RNAs pulled down by LINE1 or Malat1 ChIRP probes, expressed as 
RNA-ChIRP % input. Data are mean +/- s.e.m, n=3 independent experiments.  
(B) ChIRP-qPCR analysis for ChIRP positive control, Malat1, confirming that Malat1 RNA, but not LINE1 RNA, is 
highly associated with Malat1 and Neat1 genomic loci. Data are mean +/- s.e.m, n=3 independent experiments.  
(C) ChIRP-qPCR analysis with control or LINE1 primers, indicating that LINE1 RNA is found associated with LINE1 
DNA. Data are mean +/- s.e.m, n=3 independent experiments. 
(D) RIP assay performed with or without DNase treatment before immunoprecipitations, indicating that the Nucleolin 
(Ncl)-LINE1 RNA association is DNase-independent. Data are representative of 2 independent experiments and 
shown as mean +/- s.e.m, n=3 technical replicates.  
(E) Nuclear enrichment of the indicated RNAs taken form RIP input expression data. RNA expression is shown 
relative to cytoplasmic RNA, Gapdh. Data are mean +/- s.e.m, n=3 independent experiments.  
(F) qRT-PCR showing knockdown of candidate 2C/Dux repressors alongside Dux and 2C gene expression. Data are 
representative of two independent experiments and are mean +/- s.e.m., n=3 technical replicates. (G-H) Confirmation 
of Ncl knockdown, (G) at the RNA level, by qRT-PCR, and (H) at the protein level, by Western blotting. Images in (H) 
were spliced together to remove unrelated lanes.  
(I) Expression of MERVL repeats in RNA-seq data upon knockdown of Ncl, showing mean +/- s.e.m, n=3 biological 
replicates.  
(J) GSEA analysis of RNA-seq data upon Ncl knockdown, showing a preferential downregulation of ribosomal genes.  
(K) Colony formation assays performed in ES cells plated 24h after transfection with the indicated siRNAs. Data are 
mean +/- s.e.m, n=3 biological replicates. 
(L) qRT-PCR analysis performed in ES cells 48h after transfection with the indicated siRNAs, showing that the 
induction of 2C genes upon Ncl KD depends on Dux expression. Data are mean +/- s.e.m, n=3 technical replicates, 
representative of three experiments. 
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Figure S6, related to Figure 6. LINE1, Nucleolin and Kap1 coordinately regulate rDNA and Dux, localized at 
peri-nucleolar regions in ES but not 2C-like cells.  
(A) Scatter graph comparing gene expression changes upon LINE1 KD (this study) with changes upon Kap1 deletion 
(Ecco et al., 2016), with the indicated Spearman’s correlation coefficient. Dux targets are shown in red.  
(B) Nascent RNA expression for ribosomal protein coding genes or rRNA upon KD of Ncl, LINE1 or Kap1. Data are 
mean +/- s.e.m, n=3 biological replicates. 
(C-D) qRT-PCR confirmation that KD of LINE1 by (C) ASOs or (D) siRNAs does not alter Ncl RNA expression. Data 
are mean +/- s.e.m, n=3 biological replicates, n.s., not significant.  
(E) Western blot analysis of protein extracts from ES cells treated with RC or LINE1 ASOs, confirming that Kap1 and 
Ncl protein levels are unaffected.  
(F) Co-IP assays performed in ES nuclear extracts 48h after nucleofection with RC/LINE1 ASOs, demonstrating that 
Ncl and Kap1 still interact in the absence of LINE1 RNA. 
(G) Immunofluorescence analysis of Ncl and Kap1 proteins in 2C-GFP cells, showing no change between ES and 
2C-like states. Green arrows in (G-H) denote 2C-GFP positive cells.  Scale, 10m. 
(H) Representative immunofluorescence images and quantification of the number of nucleoli per cell in ES vs 2C-like 
cells. 2C-like cells were identified by positive 2C-GFP signal and absence of Oct4. ****P<0.0001, Chi-squared test. 
Scale, 10m, n=number of cells. 
(I) Representative co-immunofluorescence/DNA-FISH images and example scoring for each Dux localization pattern. 
Each locus was scored as associated with the lamina (L), nucleolus (N), or nucleoplasm (P). Nucleoli were stained 
with anti-Ncl, and 2C-GFP cells with anti-GFP antibodies. Scale, 2m . 
(J) Example images of Dux localization in unsorted 2C-GFP cells, showing identification of 2C-like cells by GFP-
staining and nucleoli by anti-Ncl. Dux loci are indicated by white arrows, and a 2C-like cell by a green arrow. Scale, 
10m. 
(K) Quantification of the proportion of ES or 2C-like cells containing at least one nucleoplasmic Dux locus vs no 
nucleoplasmic loci. Statistics are calculated by Chi-squared test for the indicated number (n) of cells. 
 
Figure S7, related to Figure 7. LINE1 is essential for pre-implantation development.  
(A) Developmental progression to blastocyst of the indicated Uninjected, Control ASO or LINE1 ASO injected 
embryos. Data shown are the percent of all embryos from 3 independent experiments at the indicated developmental 
stage, n=number of embryos. 
(B) Analysis of chromatin accessibility in late 2C embryos following zygote ASO microinjections by DNase-TUNEL 
experiments. Intensities are calculated per nucleus and data shown as mean +/- s.d for the number (n) of nuclei, in 
data combined from 2 independent experiments for each assay. Nuclei are counterstained by Hoechst. Scale, 20m. 
(C) Immunofluorescence for global repressive chromatin marks H3K9me2/3, quantified as in (C). Scale, 20m. 
(D) Rates of developmental progression to blastocyst in embryos cultured from the 2C stage with or without CX-5461. 
P-values in (A-B and I) are calculated by Chi-squared test, n=number of embryos. 
(E) PCA plot of all genes across all samples, showing that samples are separated firstly by developmental stage, and 
secondly by ASO microinjection, according to global gene expression profiles. 
(F) FPKM-normalized RNA-seq data from (Wu et al., 2016) demonstrating the 6 separate gene clusters identified by 
K-means clustering. Cluster 4 contains early-2C genes such as Dux itself. 
(G) RNA-seq normalized, log2-transformed expression for late 2C genes (which peak in expression in late-2C/4C 
stage), Ddit4l and Dub1a, in the indicated embryo samples. N=3 independent batches of embryos were sequenced 
per condition. *FDR <0.05, ****FDR<0.0001, Toptable analysis. 
(H) GSEA analysis showing that ribosomal genes are preferentially downregulated in 4C embryos after LINE1 KD. 
(I) Developmental progression rates to blastocyst in embryos following late-2C microinjection with ASOs, in embryos 
collected from 2 independent experiments, n=number of embryos.  
(J) qRT-PCR expression analysis of the indicated 2C genes in 4C embryos after late-2C ASO microinjections. Data 
are mean+/- s.e.m, n=3 technical replicates, for the indicated independent batches of embryos. 
(K) Expression data from (Wu et al., 2016) illustrating the expression levels of Kap1/Ncl during pre-implantation 
development. Data are FPKM, normalized to expression level in the zygote.  
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead 
Contact, Miguel Ramalho-Santos (mrsantos@ucsf.edu,  mrsantos@lunenfeld.ca). 
 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Mice 
Animal experiments were performed with 5-8-week-old female and 2-6-month-old male C57BL/6 mice. Animals were 
maintained on 12 h light/dark cycle and provided with food and water ad libitum in individually ventilated units. Animal 
experiments in USA were   in accordance with the guidelines of the UCSF Institutional Animal Care and Use 
Committee,   protocol AN091331-03. Animal experiments in UK were approved by the University of Edinburgh's 
Animal Welfare and Ethical Review Board (AWERB) and carried out under the authority of a UK Home Office Project 
License. 
 
Mouse ES cell culture 
Mouse E14Tg2A (E14) ES cells (male) were used for all experiments (Hooper et al., 1987), except for p53-/- ES cells 
(Sabapathy et al., 1997), which are V6.5-derived (male, a gift from Scott Oakes). ES cells were cultured on 0.1% 
gelatin-coated plates in ES-FBS culture medium (high glucose DMEM GlutaMAX with sodium pyruvate (Thermo 
Fisher Scientific), 15% FBS (Atlanta Biologicals), 0.1mM non-essential amino acids, 50 U/mL penicillin-streptomycin 
(UCSF Cell Culture Facility), 0.1mM 2-Mercaptoethanol (Millipore) and 1,000U/ml LIF supplement (ESGRO, 
Millipore). Where indicated, ES cells were grown in N2B27/2i/LIF conditions (DMEM/F-12, Neurobasal medium, 1x 
N2/B27 supplements, 1µM PD0325901, 3µM CHIR99021, LIF as above) according to (Ying et al., 2008) for at least 
4 passages before being used for experiments. Deletion of Kap1 in CreERT2;Kap1fl/fl ES cells (undetermined sex, 
Rowe et al., 2010) was performed in ES/FBS conditions with 1M 4-OHT overnight and analyzed 4 days later. Routine 
testing of E14 ES cells revealed absence of mycoplasma contamination. ES cells were not genotyped. 
 
2C-GFP ES cell line 
2C-GFP reporter ESCs were generated as in (Ishiuchi et al., 2015), using Addgene plasmid 69071, from parental 
E14 ES cells. 4x106 cells were nucleofected with 4µg linearized 2C-GFP plasmid, and plated at low density in 10cm2 
plates. Selection was performed with 250µg/mL G418 (Mirus) commencing 36h after nucleofection and maintained 
for 8 days before individual colonies were picked and expanded. A clone with high, specific upregulation of 2C genes 
in sorted GFP+ cells (Figure S2K) was used for all experiments.  
 
MEFs 
E13.5 primary MEFs derived from pooled CD1 embryos (mixed sex) were cultured in MEF medium (as ES-FBS but 
without 2-Mercaptoethanol and LIF), and used within 4 passages of initial derivation. 
 
 
METHOD DETAILS 
 
ASO- and siRNA-Mediated Knockdown 
A morpholino ASO targeting the inter-ORF region of LINE1 was designed with software available at Gene Tools LLC. 
The morpholino chemical backbone was chosen because of its stability, specificity and extensive use in pre-
implantation mouse embryos [(e.g., (Lin et al., 2013)]. ASOs have been shown to be potent inhibitors of nuclear 
RNAs, such as lncRNAs (Lennox and Behlke, 2016). The LINE1 ASO was validated in silico to be perfectly 
homologous to at least 500 full-length LINE1 elements, using L1Base (Penzkofer et al., 2005). This sequence was 
verified by Blast as not having homologies to any known Refseq mRNAs. The reverse complement of the LINE1 ASO 
sequence does not target LINE1 RNA and was used as a control (RC ASO). In the indicated embryo experiments, a 
standard non-targeting control ASO (Gene Tools) was also used. Both lissaminated (cell line experiments) and non-
lissaminated (embryo experiments) ASOs were utilized. ASOs were introduced into cells by nucleofection, utilizing 
an Amaxa Nucleofector 2b device and ES nucleofection kit (Lonza), according to the manufacturer’s instructions. 4-
5 million cells were used per nucleofection together with 5nmol of the indicated ASO. Cells were plated in ES medium 
immediately following nucleofection and left to recover for 24-48h. For colony formation assays and expression 
analyses excluding co-transfections with siRNAs, Lissamine-positive ES cells were purified by FACS utilizing a BD 
FACSAria II (BD Biosciences) to enrich for successfully-nucleofected cells. Nucleofection efficiency was routinely 
70% or above. All other experiments were performed on the bulk population of nucleofected cells without prior 
enrichment for ASO-positive populations. siRNA transfections were performed in ES cells with Lipofectamine 2000 
(Thermo Fisher Scientific) as described previously (Percharde et al., 2012). ES cells were plated 5-7h before 
transfection at a density of 5x105 ES cells per 6-well culture area and transfected with 100 pmol siRNA, according to 
the manufacturer’s standard recommendations. A non-targeting siRNA (siGenome siControl #2, Dharmacon) was 
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used as a control. For LINE1 siRNA knockdown, 2 independent siRNA sequences were designed using online tools 
available at Dharmacon and verified to have no perfect match to other mRNAs. For combined ASO/siRNA 
experiments, ES cells were first nucleofected with ASOs, then plated and left to recover for 7h. Next, the medium 
was exchanged for fresh ES-FBS without antibiotics and siRNA transfections were performed as above. The medium 
was exchanged the next morning and cells harvested for RNA extraction approximately 48h post initial nucleofection. 
All ASO and siRNA sequences are available in Supplemental data, Table S5. 
 
Embryo Microinjection and Culture  
Females were superovulated by administration of 7.5 I.U. of pregnant mare serum gonadotropin (PMSG; National 
Hormone Pituitary Program (NHPP), Harbor-UCLA Medical Center, CA, USA or Intervet UK) and 48h later with 7.5 
I.U. of human chorionic gonadotropin (hCG; Sigma-Aldrich or Intervet UK). Embryo experiments were performed as 
described previously (Lin et al., 2013, Lin et al., 2014), and embryos were microinjected using a microinjector 
(FemtoJet 4i, Eppendorf) and an inverted microscope (Leica, DMi8) equipped with micromanipulators (Narishige). 
Zygotes were microinjected with Standard Control, RC, or LINE1 ASOs. ASO solutions were injected into the 
cytoplasm from a stock concentration of 1.5mM (1X) or 0.75mM (0.5X), utilizing 2-5 pl of solution per injection. 
Embryos were cultured in KSOM+AA medium (Millipore) at 37°C in 5% CO2. For qRT-PCR analysis in late 2C 
embryos, 10-11 embryos were collected approximately 24h post injection for RNA isolation using the PicoPure RNA 
Extraction Kit (Arcturus), or were cultured for a further 3 days to monitor developmental progression. Embryo qRT-
PCR data are normalized to Hprt expression. For embryo RNA-seq experiments, zygotes were microinjected with 
0.5X ASO and cultured in KSOM+AA medium. Early 2C embryos were collected on approximately 33 h post hCG 
(~9 h post-microinjection). 4C embryos were collected after 2 days of in vitro culture. ASO injections at the late 2-cell 
stage were performed after collection approximately 43h post hCG administration, and 1X ASOs were microinjected 
into the cytoplasm of both blastomeres. Developmental progression to blastocyst was monitored, or 4C embryos 
were collected on the day following injection for RNA isolation and qRT-PCR analysis, as above. For inhibition of 
rRNA synthesis after ZGA, late 2C embryos were cultured in KSOM+AA with 1M CX-5461 or 0.1% DMSO. 
 
DNase-TUNEL Experiment 
DNase I-TUNEL assays were performed in late 2C embryos. Embryos were permeabilized by 0.5% Triton X-100 in   
pre-extraction buffer (300mM sucrose, 25mM HEPES, 1M CaCl2, 50mM NaCl, 3mM MgCl2) for 5 min before digesting 
with 0.2U/l of DNase I (NEB). Embryos were then fixed in 4% PFA. TUNEL Assays (Click-iT TUNEL Imaging assay, 
Thermo Fisher Scientific) were followed according to manufacturer’s instructions. The nuclear area was defined 
according to Hochest DNA staining and the intensity of nuclear TUNEL signal was quantified using Fiji software. 
 
RNA FISH  
Embryo RNA FISH was performed as previously described (Lin et al., 2014). Embryos were fixed in methanol, 
permeabilized in 70% ethanol and hybridized at 37°C using 48 single-molecule probes designed to span the length 
of LINE1 ORF2 RNA, designed from the sequence of L1spa (L1Md_Tf family) and expected to target the majority of 
transcribed LINE1 RNAs (Naas et al., 1998), or against 18S rRNA at 1:250 dilution. RNA-FISH in ES cells was 
performed on glass coverslips 48h after ASO or siRNA treatment, according to the manufacturer’s standard protocol 
(Biosearch Technologies). Fixation was performed in 1% paraformaldehyde (PFA) for 15 min, followed by 
permeabilization overnight in 70% ethanol at 4°C prior to hybridization. Hybridization was performed as above, using 
the probes against LINE1 RNA. Co-incubations were performed with Gapdh probes where indicated (purchased from 
Biosearch Tehnologies). For +RNase negative controls, coverslips were incubated in 2X saline-sodium citrate (SSC) 
buffer plus 10g/mL RNAse A (Thermo Fisher Scientific) for 30 min at 37°C, then washed twice in 2X SSC, prior to 
LINE1 FISH hybridizations. For LINE1 RNA FISH in ES vs 2C-like cells, GFP+/- populations of 2C-GFP reporter cells 
were separated by FACS then plated onto separate wells on matrigel-coated Lab-Tek II Chambered Coverglass for 
1h before fixation and hybridization as above. All images were collected on a Leica DMI 4000B inverted scope using 
a 100× oil-immersion objective, every 0.25μm using the Z-stack function of the MetaMorph software (Molecular 
Devices). All nuclei were counterstained with DAPI. RNA FISH foci were quantified with StarSearch online software 
[(Raj et al., 2008), Raj Lab, University of Pennsylvania], using identical threshold settings between different samples 
and images.  
 
Cell-cycle and Self-renewal Assays 
24h following nucleofection or siRNA transfection, ES cells were either trypsinized and counted manually (siRNAs) 
or isolated by FACS according to Lissamine fluorescence (ASOs); 1000 cells were plated per well of a 12-well plate 
in ES-FBS medium. Colonies were left to form over a period of 5-6 days and then fixed and stained for Alkaline 
Phosphatase (AP) according to the manufacturer’s recommendations (Sigma-Aldrich). The numbers of AP-positive 
colonies per well were manually counted. For proliferation assays, 1x106 ES cells were plated immediately following 
ASO nucleofection and then each day for the next four days the cells were trypsinized and counted, replating 1x106 
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cells each time back into culture. Cell-cycle analysis was performed according to (Bulut-Karslioglu et al., 2018) and 
the standard manufacturer’s protocol, incubating ES cells 48h after nucleofection with 10M EdU for 1 h, followed by 
analysis of EdU incorporation and DNA content with the Click-iT EdU imaging kit (Life Technologies) and FxCycle-
Violet, respectively.  
 
RNA Extraction and Expression Analysis 
For ASO-nucleofected samples, RNA was isolated from 300,000 FACS-purified ES cells using the RNeasy mini kit 
(Qiagen), according to manufacturer’s instructions. RNA was treated once on-column with DNAse I and once more 
off-column (RNAse-free DNase I from Thermo Fisher Scientific) to remove any residual DNA contamination. cDNA 
synthesis was performed from 1g RNA with the High Capacity cDNA Reverse Transcription kit (Applied Biosystems) 
and qRT-PCR performed with SYBR green (KAPA) on an ABI-Prism PCR machine. qRT-PCR analysis following 
siRNA experiments or ASO/siRNA experiments were performed as above, but without prior FACS purifications. All 
gene expression data were normalized to two independent housekeeping genes (Rpl7, Ubb or H2A). 
 
Retrotransposition Assay  
ES cells were nucleofected with 5g codon-optimized LINE1 CAG-ORFeus GF-P reporter plasmid (An et al., 2006) 
or LINE1 5’UTR-ORFeus GF-P reporter plasmid (Newkirk et al., 2017). The following morning, Stavudine (d4T, 20M) 
or Tenofovir disoproxil fumarate (TDF, 4M) (Jones et al., 2008) was added and cells cultured for a further 48h, when 
retrotransposition rates were determined by flow cytometry for GFP-positive cells, or cells harvested for RNA 
extraction as above. Colony formation assays in the presence of d4T and TDF were as above, with the addition of 
inhibitors performed 24h after plating and maintained throughout.  
 
RNA-sequencing 
Sample preparation for RNA-seq in ES cells was performed as previously described (Percharde et al., 2017b). RNA 
was extracted utilizing the RNeasy mini kit as for qRT-PCR, then 800ng DNAse-treated total RNA was used per 
library preparation according to the NEBNext Ultra Directional Library Prep Kit for Illumina (NEB). Embryo RNA-seq 
was performed in pools of 14-18 early 2C or 4C embryos per sample, with total RNA isolated using the PicoPure 
RNA Extraction Kit (Arcturus). Libraries were generated using the SMARTer Stranded Total RNA-seq Kit v2 (Takara) 
and 500pg total RNA input per sample. In all cases, three replicates were sequenced per condition at the UCSF 
Center for Advanced Technology on an Illumina HiSeq 2500 or HiSeq 4000, with 50bp single end reads.  
 
Immunofluorescence 
ES cells were plated onto matrigel-coated 8-well chambers for 1h, fixed for 10 min in 4% PFA, and blocked and 
permeabilized in one step in IF buffer (PBS, 10% donkey serum, 2.5% BSA) plus 0.4% Triton X-100. Incubations 
were performed overnight at 4ºC, using the following antibodies and dilutions in IF buffer: GFP (1:100), Oct4 (1:100), 
Nanog (1:200), Kap1 (1:500), Nucleolin (1:1000 x), Orf1p (Di Giacomo et al., 2014) (1:500). The next day, slides 
were washed 3 times in PBS, incubated for 60 min in the relevant fluorescently-conjugated secondary antibodies 
(1:1000 in IF buffer, Life Technologies), and washed again as before. Slides were mounted with Vectashield 
containing DAPI and imaged on a Leica SP5 upright confocal microscope at 63X magnification under oil immersion. 
Embryo immunofluorescence (IF) experiments were performed as above, except blocking was performed in 5% BSA 
and incubation with primary antibodies was at 37℃ for 1.5 hr. with antibodies against H3K9me2 or H3K9me3 (1:50), 
and nuclei counterstained with DAPI. Images of stained embryos were acquired by a spinning disk confocal (CSU-
W1, Yokogawa) on an upright microscope frame (BX-63, Olympus) using a 60x silicon oil immersion objective 
(UPLSAPO 60XS2, Olympus) with additional 2x intermediate magnification. IF signal intensity was quantified using 
Fiji software.    
 
RNA Immunoprecipitation (RIP)  
RIP experiments were performed on nuclear extracts according to a standard Abcam protocol, with the following 
modifications. 1g anti-Nucleolin or control IgG antibodies were pre-bound to 30L Protein A Dynabeads (Thermo 
Fisher Scientific) and incubated rotating for at least 3h at 4°C. Beads were next collected on a DynaMag (Thermo 
Fisher Scientific) and resuspended in RIP buffer (150mM KCl, 25mM Tris pH 7.4, 5mM EDTA, 0.5mM DTT, 0.5% 
NP40, protease and RNase inhibitors) containing 500ng/L tRNA (Thermo Fisher Scientific) and 1 mg/mL RNase-
free BSA (bioWORLD) to block for 30 min, then collected and used immediately in RNA immunoprecipitation. Where 
indicated, 40U of Turbo DNase (Thermo Fisher Scientific) was added to nuclear extracts and incubated for 30 min at 
37 °C, then quenched with 10mM EDTA, before continuing with immunoprecipitations. Prior to immunoprecipitation, 
ES nuclear extracts were also blocked for 30 min with 20l Protein A Dynabeads at 4°C, 30 min. Cleared nuclear 
lysates were incubated together with antibody-bound blocked beads overnight at 4°C. The next day, lysates were 
washed four times in RIP buffer, once in PBS, and RNA was extracted from beads using Trizol and standard phenol-
chloroform extraction. The aqueous phase containing the RNA was loaded onto RNeasy mini columns (Qiagen) with 
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2x volume of 100% ethanol and RNA was purified according to the standard protocol. RNA was DNAse I treated 
twice as before and used to generate cDNA for qRT-PCR.  
 
Nascent Transcription and Translation Assays 
For nascent transcription assays, ES cells were cultured for 45 min in normal ES medium supplemented with 1mM 
EU. For nascent translation assays, cells were incubated in HPG medium (as ES-FBS medium with the following 
substitutions: Methionine- and Cysteine-free DMEM, 1mg/mL BSA instead of FBS) for 30 min, followed by HPG 
medium plus 50M HPG for 45 min. Following incubations, cells were collected by trypsinization, fixed, and 
permeabilized, and nascent RNA or proteins were labelled using the Click-iT Alexa Fluor 488 RNA or Protein 
Synthesis Assay Kit (Thermo Fisher Scientific). All samples were analyzed on a LSR II Flow Cytometer (BD 
Biosciences). Relative EU or HPG incorporation was quantified by comparing the EU/HPG median fluorescence 
intensity between LINE1 and RC nucleofected samples, and carried out 24-48h after nucleofection. 
 
Nascent RNA capture followed by qRT-PCR 
EU incorporation was performed as above, with the exception that incubations were with 0.4mM EU for 30 min. 
Where indicated, CX-5461 was added in the morning prior to EU addition, for a total of 8h treatment. ES cells were 
washed, collected by trypsinization, counted, and 2x105 were used to extract RNA. Nascent RNAs was captured 
according to standard protocols within the Click-iT Nascent RNA Capture Kit (Invitrogen), and used in qRT-PCR 
assays with the indicated primer sets (see Table S5 for sequences). 
 
Chromatin Isolation by RNA Precipitation 
ChIRP was performed according to (Yin et al., 2015) with some modifications. 59nt DNA probes were biotinylated 
through terminal transferase (NEB) with Bio-N6-ddATP (ENZO) as substrate. E14 ES cells were harvested by trypsin 
digestion and crosslinked with 2mM dithiobis(succinimidyl propionate), (DSP, Thermo Scientific) in PBS at room 
temperature for 30 min with gentle end to end rotation. Formaldehyde was added to a final concentration of 3.7% to 
crosslink for 10 min further, then quenched with 250mM Glycine at room temperature for 5 min. ES cells were 
centrifuged and the pellet was washed with ice-cold PBS for 3 times, then snap frozen in liquid nitrogen and stored 
at -80℃. Crosslinked cells (~1×107) were resuspended with 500µl DNase I digestion solution (20mM Tris-HCl, pH7.5, 
5mM MgCl2, 0.5mM CaCl2, 0.5% Triton X-100) with 1/20 volume of vanadyl ribonucleoside complex (VRC, NEB), 
2.5µl protease inhibitors and 2.5µl 200mM PMSF. Dnase I was added to a final concentration of 12 U/ml; the reaction 
was rotated for 10 min at 37℃ and stopped with 20mM EDTA. Chromatin was pelleted, washed once with nuclear 
lysis buffer (NLB, 50mM Tris-HCl, pH7.5, 10mM EDTA, 1% SDS, inhibitors) and sonicated in NLB (5 cycles of: 25% 
amplitude, 6 sec on, 15 sec off, Vibra-Cell™ Ultrasonic Liquid Processors). Insoluble material was removed by 
centrifugation and the supernatant used for ChIRP experiments. For the Rnase treatment control, samples were 
treated with 10g/ml Rnase A/T1 at 37℃ for 20 min. For hybridization, samples were incubated with 20pmol probes 
per 200µl lysate, supplemented with ¼ volume of 5x hybridization buffer (50mM Tris-HCl, pH7.5, 10mM EDTA, 1.5M 
NaCl, 50% formamide). The hybridization was conducted at 39℃ rotating for 3h. 50l pre-balanced streptavidin M280 
beads were then added and the incubation continued for an additional 3h. The beads were washed 5 times total with 
0.2× SSC wash buffer (0.1×SSC, 1% SDS) at 42℃. For the Rnase treatment control, after 3 times of washing, the 
beads were treated once with 10g/ml Rnase A/T1 at 37℃ in Rnase digestion buffer (50mM Tris-HCl, pH7.5, 75mM 
NaCl, 1mM DTT), before washing two more times. To elute, the beads were washed once with SDS elution buffer 
(50mM Tris-HCl, 5mM MgCl2, 75mM NaCl, 1% SDS) at 39℃ for 20 min, and once with elution buffer (50mM Tris-
HCl, 5mM MgCl2, 75mM NaCl, 0.1% Triton X-100) at 39℃ for 5 min. DNA was eluted from the beads by RNAse H 
treatment in two sequential incubations with Rnase H (NEB) at 37℃ for 20 min, and with SDS elution buffer at room 
temperature, 2 min, combining all eluents. Crosslinking was reversed by treatment with 0.1g /l protease K, 150mM 
NaCl, and 10mM EDTA at 65℃ overnight and the DNA was purified using the MinElute PCR Purification Kit 
(QIAGEN). ChIRP enrichments were analyzed by qPCR of the purified DNA. For RNA-ChIRP analysis, beads were 
boiled in NLB after the 0.1x SSC washes, then further reverse-crosslinked by boiling at 95℃ for 30 min in the presence 
of 1mM DTT. Reverse crosslinked RNA was purified using Trizol and processed for qRT-PCR analysis as for other 
RIP RNA samples. 
 
DNA FISH  
Co-staining of Dux DNA-FISH and immunofluorescence followed a protocol modified from what was previously 
described (Guan et al., 2017). The sequences of 22 ssDNA oligos to tile the 5kb genomic region of one Dux repeat 
unit were designed via OligoArray2.1 (Rouillard et al., 2003), synthesized by IDT with 5’ amino modifications, pooled 
together in equimolar ratio, and covalently labeled with Cy3. For immunofluorescence combined with Dux DNA-FISH 
experiments, 2C-GFP ES cells were seeded onto Lab-Tek II Chambered Coverglass coated with Matrigel for 1h, then 
fixed 5 min with 4% paraformaldehyde followed by an ice-cold MeOH wash for 5 min on ice. Samples were then 
incubated with 80% (v/v) formamide at 80ºC for 10 min followed by a PBS wash for 1 min. Cells were next incubated 
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in IF blocking buffer (2.5% BSA, 0.4% Triton in PBS) at room temperature for 30 min. The hybridization of oligo 
probes to the Dux repeat region was achieved in 5 min at room temperature in a solution containing 50% (v/v) 
formamide, 2x SSC, and 1M oligo probes followed by a wash of 40% (v/v) formamide at room temperature for 3 
min. Samples were next incubated with primary antibodies against Nucleolin and GFP in IF blocking buffer for 30 min 
at room temperature followed by incubation with secondary antibodies (Alexa Fluor, 1:3000) for 30 min at room 
temperature, and nuclei counterstained with DAPI. Fluorescence images were taken on an inverted microscope with 
100x (N.A.=1.4) oil objective using X-Cite LED illumination in DAPI, GFP, RFP, and Cy5 channels, utilizing an Andor 
Zyla sCMOS camera for detection (Nikon Imaging Center at UCSF).  The image stacks were acquired with a spinning 
disk confocal module with 0.25m in z-step. For scoring of Dux localization, all images were analyzed in Fiji, 
identifying individual z-stacks containing one locus, then comparing across Nucleolin or DAPI channels to identify 
overlap or co-localization with nucleoli, edges of nuclei (lamina), or nucleoplasm. Positive GFP signal was used to 
identify 2C-like cells and score localization for each Dux locus in each ES vs 2C-like cell. Data were collected and 
quantified from two separate FISH experiments across multiple individual chambers.  
 
Chromatin Immunoprecipitation (ChIP)  
Low-cell histone ChIP was performed starting from 5x105 Lissamine-positive ES cells purified by FACS 48h after 
ASO nucleofection. Cells were fixed in suspension for 8 min in 1% formaldehyde, washed and the pellets snap frozen. 
Chromatin was prepared utilizing reagents and the protocol from Low Cell Number ChIP Kit (Diagenode). Cell pellets 
were thawed, lysed and sonicated using a Covaris S220 focused-ultrasonicator for 8 cycles with the following 
conditions: 60 sec per cycle, duty cycle 2%, 200 cycles per burst, intensity 3. IPs and washes were performed 
according to kit protocols, utilizing 1x105 cells per IP. For transcription factor ChIP, chromatin fixation and preparation 
of nuclear extracts were performed as described previously (Stock et al., 2007). ES cells were fixed and washed as 
above, then incubated in swelling buffer (25mM HEPES pH 7.9, 1.5mM MgCl2, 10mM KCl, 0.1% NP-40) for 30 min 
on ice with frequent vortexing and passed 5 times through a 25G needle to shear cell membranes. Nuclei were 
pelleted by centrifugation then resuspended in sonication buffer (50mM HEPES pH 7.9, 140mM NaCl, 1mM EDTA, 
1% Triton X-100, 0.1% Sodium deoxycholate, 0.1% SDS) and incubated on ice a further 30 min before proceeding 
to sonication. Swelling and sonication buffers were supplemented with the following inhibitors fresh each time: 1x 
Halt Protease Inhibitor Cocktail (Thermo Fisher Scientific), 5mM sodium fluoride, 5mM sodium butyrate, 1mM PMSF, 
along with 10mM N-ethylmaleimide (NEM) (Thompson et al., 2015). Chromatin samples were sonicated using a 
Covaris S220 focused-ultrasonicator for 14 cycles with the following conditions: 60 sec per cycle, duty cycle 5%, 200 
cycles per burst, intensity 4. Resultant DNA fragments were of an average length of 200-500bp. Immunoprecipitations 
were carried out overnight at 4°C with 20g chromatin, 3g Kap1/control antibody or 0.4g Nucleolin antibody, and 
30L Protein A/G Dynabeads per IP. ChIP washes were performed the following day as follows: twice in low-salt 
buffer (20mM Tris-HCl pH 8, 0.1% SDS, 1% Trixon X-100, 2mM EDTA, 150mM NaCl), once in high-salt buffer (as 
above but with 500mM NaCl), once in LiCl wash buffer (10mM Tris-HCl pH 8, 250mM LiCl, 0.5% NP-40, 0.5% sodium 
deoxycholate, 1mM EDTA), once in TE buffer, all for 7 min at 4°C for each wash. Finally, Dynabeads containing 
immune complexes along with input samples were resuspended in elution buffer (50mM sodium bicarbonate, 50mM 
Tris-Hcl pH 8, 1% SDS, 1mM EDTA) containing 100ug/mL RNAse A (Thermo Fisher Scientific) and incubated for 30 
min at 37°C. Crosslinks were next reversed by addition of 0.5mg/mL Proteinase K (Ambion) and incubation at 55°C 
shaking for at least 2h. DNA was purified with QIAquick PCR purification columns (Qiagen) and ChIP enrichments 
analyzed by qPCR. ChIP enrichments were calculated as % input and normalized to enrichment at the negative 
control region, intergenic chr11, int-chr11 for each experiment. Primer sequences are listed in Table S5. 
 
Western blotting  
Whole cell extracts were prepared from ES cells in ice-cold RIPA buffer containing protease-inhibitors (as for ChIP 
but minus NEM). Proteins were separated on 4-15% Mini-Protean TGX SDS Page gels (BioRad) and transferred to 
PVDF membranes. Blocking was performed for 45 min in 5% milk/PBS-T buffer followed by incubation overnight with 
primary antibodies at 4°C. The following day, membranes were incubated with the appropriate anti-mouse/rabbit 
secondary antibodies conjugated to HRP (Jackson) for 1h, and proteins were detected by ECL or ECL Plus reagent 
and autoradiography. 
 
Co-immunoprecipitation (Co-IP)  
Co-IP assays were performed on nuclear extracts. Cell pellets were resuspended in hypotonic buffer (10mM HEPES 
pH 7.9, 5mM MgCl2, 0.25M Sucrose, 0.1% NP40, protease inhibitors). Cell suspensions were passed through an 
18G needle, incubated for 10 min on ice and centrifuged. The resulting pellet was resuspended in nuclear extraction 
buffer (10mM HEPES pH7.9, 1mM MgCl2, 0.1mM EDTA, 0.5M NaCl, 0.5% Triton X-100, 25% glycerol, protease 
inhibitors). The nuclear suspension was passed through an 18 G needle, incubated on ice for 30 min, sonicated in a 
Bioruptor (Diagenode) for 5 min at 30 sec on, 30 sec off and centrifuged at 4000 rpm for 10 min in a benchtop 
centrifuge at 4°C. Supernatants containing nuclear extracts were quantified using a Pierce BCA protein assay kit 
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(Thermo Fisher Scientific), and 100g nuclear extracts were immunoprecipitated using the indicated primary 
antibodies, rotating overnight at 4°C. The following day, immune complexes were bound to Protein A/G Dynabeads 
(Thermo Fisher Scientific), washed 3 times in nuclear extraction buffer at 4°C 10 min, boiled in LDS Sample Buffer 
(Thermo Fisher Scientific) and used for western blotting analysis.   
 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
 
RNA-seq analysis 
RNA-seq reads were quality-checked, trimmed, and aligned to reference genome mm9 using Tophat2 (Kim et al., 
2013) and default settings, apart from for TE analysis where reads were aligned using Tophat2 setting g -1 to map 
each TE to one random location. Reads were counted for each gene or TE family using the Subread package, 
FeatureCounts (Liao et al., 2013), and data normalized utilizing DEseq2 in R/Bioconductor (Love et al., 2014). All 
other RNA-seq analyses and statistics were performed in R/Bioconductor utilizing custom R scripts. For 
transcriptional analysis of Dux targets, these were identified as the set of genes detected in our dataset that are most 
highly induced by Dux over-expression in ES cells (Hendrickson et al., 2017), which we verified to be directly bound 
by Dux in over 70% of cases (Hendrickson et al., 2017). 
 
Statistical analysis  
All statistical analyses were performed with Graphpad Prism 7.0 software, except genome-wide data analyses which 
were performed in R/Bioconductor. Details of individual tests are outlined within each figure legend, including number 
and type of replication performed (n) and the reported error either as standard deviation (s.d) or standard error of the 
mean (s.e.m). All statistics are * P <0.05, ** P <0.01, *** P < 0.001, **** P <0.0001 and calculated by two-tailed 
Student’s t-test unless specifically noted otherwise in the legend. Welch’s correction was applied to t-tests whenever 
the variance was unequal between conditions. 
 
 
DATA AND SOFTWARE AVAILABILITY 
 
The accession number for the sequencing data reported in this paper is GEO: GSE100939. 
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Supplemental Item Titles 
 
Table S1, related to Figure 2. Toptable analysis of differentially expressed genes and TEs upon LINE1 KD with 
ASOs 
Table S2, related to Figure 3. Toptable analysis of differentially expressed genes and TEs upon LINE1 KD with 
ASOs, with or without KD of Dux. 
Table S3, related to Figure 5. Toptable analysis of differentially expressed genes and TEs upon Nucleolin KD. 
Table S4, related to Figure 7. Toptable analysis of differentially expressed genes in early-2C or 4C embryos upon 
LINE1 KD with ASOs. 
Table S5, related to STAR methods. Oligo and probe sequences used in this study. 
 
 KEY RESOURCES TABLE 
The table highlights the genetically modified organisms and strains, cell lines, reagents, software, and 
source data essential to reproduce results presented in the manuscript. Depending on the nature of the 
study, this may include standard laboratory materials (i.e., food chow for metabolism studies), but the 
Table is not meant to be comprehensive list of all materials and resources used (e.g., essential chemicals 
such as SDS, sucrose, or standard culture media don’t need to be listed in the Table). Items in the Table 
must also be reported in the Method Details section within the context of their use. The number of 
primers and RNA sequences that may be listed in the Table is restricted to no more than ten each. If 
there are more than ten primers or RNA sequences to report, please provide this information as a 
supplementary document and reference this file (e.g., See Table S1 for XX) in the Key Resources Table. 
Please note that ALL references cited in the Key Resources Table must be included in the 
References list. Please report the information as follows: 
 REAGENT or RESOURCE: Provide full descriptive name of the item so that it can be identified and 
linked with its description in the manuscript (e.g., provide version number for software, host source 
for antibody, strain name). In the Experimental Models section, please include all models used in the 
paper and describe each line/strain as: model organism: name used for strain/line in paper: 
genotype. (i.e., Mouse: OXTRfl/fl: B6.129(SJL)-Oxtrtm1.1Wsy/J). In the Biological Samples section, 
please list all samples obtained from commercial sources or biological repositories. Please note that 
software mentioned in the Methods Details or Data and Software Availability section needs to be 
also included in the table. See the sample Table at the end of this document for examples of how to 
report reagents. 
 
 SOURCE: Report the company, manufacturer, or individual that provided the item or where the item 
can obtained (e.g., stock center or repository). For materials distributed by Addgene, please cite the  
article describing the plasmid and include “Addgene” as part of the identifier. If an item is from 
another lab, please include the name of the principal investigator and a citation if it has been 
previously published. If the material is being reported for the first time in the current paper, please 
indicate as “this paper.” For software, please provide the company name if it is commercially 
available or cite the paper in which it has been initially described. 
 
 IDENTIFIER: Include catalog numbers (entered in the column as “Cat#” followed by the number, 
e.g., Cat#3879S). Where available, please include unique entities such as RRIDs, Model Organism 
Database numbers, accession numbers, and PDB or CAS IDs. For antibodies, if applicable and 
available, please also include the lot number or clone identity. For software or data resources, 
please include the URL where the resource can be downloaded. Please ensure accuracy of the 
identifiers, as they are essential for generation of hyperlinks to external sources when available. 
Please see the Elsevier list of Data Repositories with automated bidirectional linking for details. 
When listing more than one identifier for the same item, use semicolons to separate them (e.g. 
Cat#3879S; RRID: AB_2255011). If an identifier is not available, please enter “N/A” in the column.   
o A NOTE ABOUT RRIDs: We highly recommend using RRIDs as the identifier (in particular for 
antibodies and organisms, but also for software tools and databases). For more details on how 
to obtain or generate an RRID for existing or newly generated resources, please visit the RII or 
search for RRIDs. 
 
Please use the empty table that follows to organize the information in the sections defined by the 
subheading, skipping sections not relevant to your study. Please do not add subheadings. To add a row, 
place the cursor at the end of the row above where you would like to add the row, just outside the right 
border of the table. Then press the ENTER key to add the row. Please delete empty rows. Each entry 
must be on a separate row; do not list multiple items in a single table cell. Please see the sample table at 
the end of this document for examples of how reagents should be cited. 
  
Key Resource Table
 TABLE FOR AUTHOR TO COMPLETE 
Please upload the completed table as a separate document. Please do not add subheadings to the Key 
Resources Table. If you wish to make an entry that does not fall into one of the subheadings below, please contact 
your handling editor. (NOTE: For authors publishing in Current Biology, please note that references within the KRT 
should be in numbered style, rather than Harvard.) 
 
KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Anti-H3K9me2, mouse monoclonal Abcam Cat# ab1220, 
RRID:AB_449854 
Anti-H3K9me3, rabbit polyclonal Abcam Cat# ab8898 
RRID:AB_306848 
Anti-H3K27me3, rabbit monoclonal Millipore Cat# 04-745 
RRID:AB_1163444 
Anti-Kap1, mouse monoclonal Abcam Cat# ab22553 
RRID:AB_447151 
Anti-Nucleolin, rabbit polyclonal Abcam Cat# ab22758 
RRID:AB_776878 
Anti-GFP, chicken polyclonal Aves Labs Cat# GFP-1020 
RRID:AB_10000240 
Anti-Oct3/4, mouse monoclonal Santa Cruz 
Biotechnology 
Cat# sc5279 
RRID:AB_628051 
Anti-Nanog, rabbit polyclonal Abcam Cat# ab80892 
RRID:AB_2150114 
Anti-Orf1p, rabbit polyclonal Donal O’Carroll (Di Giacomo et al., 
2014) 
Anti-Gapdh, mouse monoclonal Millipore Cat# MAB374, 
RRID:AB_2107445 
Anti-Actin, rabbit polyclonal Abcam Cat# ab8227, 
RRID:AB_2305186 
Normal rabbit IgG Abcam Cat# ab46540, 
RRID:AB_2614925 
Bacterial and Virus Strains  
   
Biological Samples   
   
Chemicals, Peptides, and Recombinant Proteins 
CX-5461, Pol I inhibitor Selleckchem or 
Xcessbio 
Cat# S2684 or 
M66052 
LIF Millipore Cat# ESG1107 
PD0325901 Stemgent Cat# 04-0006 
CHIR99021 Selleckchem Cat# S2924 
B27 supplement 50x Life Technologies Cat# 17504044 
N2 supplement 100x Life Technologies Cat# 17502048 
Fetal bovine serum Atlanta Biologicals Cat# S11150 
d4T (Stauvidine) NIAID; 
https://www.aidsreage
nt.org/Index.cfm 
Cat# 10200 
 TDF (Tenofovir disoproxil fumarate) NIAID; 
https://www.aidsreage
nt.org/Index.cfm 
Cat# 10198 
G418, 50mg/mL Mirus Cat# MIR 5920 
RNase-free yeast tRNA Thermo Fisher 
Scientific 
Cat# AM7119 
RNase-free BSA bioWORLD Cat# 40200064-1 
Vanadyl ribonucleoside complex (VRC) NEB Cat# S1402S 
Turbo DNase Thermo Fisher 
Scientific 
Cat# AM2238 
DNase-1 Amplification grade (off-column treatment) Thermo Fisher 
Scientific 
Cat# 18068015 
N-ethylmaleimide (NEM) Sigma Aldrich Cat# E3876-5G 
Dithiobis(succinimidyl propionate) (DSP) Thermo Fisher 
Scientific 
Cat# 22585 
RNase A/T1 Thermo Fisher 
Scientific 
Cat# EN0551 
Critical Commercial Assays 
Protein A Dynabeads Thermo Fisher 
Scientific 
Cat# 10002D 
Protein G Dynabeads Thermo Fisher 
Scientific 
Cat# 10003D 
Diagenode Low Cell ChIP kit Diagenode Cat# C01010070 
NEBNext Ultra Directional Library Prep kit NEB Cat# E7420S 
SMARTer Stranded Total RNA-seq kit v2 Pico Input 
Mammalian 
Takara Cat# 634411 
NEBNext Multiplex Oligos for Illumina (set 1) NEB Cat# E7335S 
NEBNext Multiplex Oligos for Illumina (set 2) NEB Cat# E7500S 
Agilent RNA 6000 Pico kit  Agilent Cat# 5067-1513 
Agilent High Sensitivity DNA kit Agilent  Cat# 5067-4626 
RNeasy Mini/Micro kits Qiagen Cat# 74104/4 
PicoPure RNA Extraction kit Arcturus Cat# KIT0204 
Click-iT Nascent RNA Capture kit Life Technologies Cat# C10365 
Click-iT RNA Alexa Fluor 488 HCS Assay kit Life Technologies Cat# C10327 
Click-iT HPG Alexa Fluor 488 Protein Synthesis Assay 
kit 
Life Technologies Cat# C10428 
Click-iT EdU Alexa Fluor 488 Flow Cytometry Assay Kit Life Technologies Cat# C10420 
Mouse ES cell Nucleofector Kit Lonza Cat# VPH-1001 
Red Alkaline Phosphatase staining kit VECTOR Cat# SK-5100 
   
Deposited Data 
Raw and processed RNA-sequencing data This paper GEO: GSE100939 
RNA-sequencing data in ES cells upon Kap1 deletion (Ecco et al., 2016) GEO: GSE74278 
   
Experimental Models: Cell Lines 
Mouse ES cells: E14Tg2A B.Skarnes (Hooper et al., 1987) 
Mouse ES cells: E14:2C-GFP This paper N/A 
Mouse ES cells: CreERT2;Kap1fl/fl D. Trono (Rowe et al., 2010) 
 Mouse ES cells: p53-/- (V6.5 derived) E.F. Wagner  (Sabapathy et al., 
1997) 
MEFs This paper N/A 
   
Experimental Models: Organisms/Strains 
Mice: C57BL/6NCrl Charles River Cat# 027 
Oligonucleotides 
Control ASO: 
CCTCTTACCTCAGTTACAATTTATA 
Gene Tools N/A 
RC ASO: 
AGACAGCCACAAGAACAGAATGCCA 
This paper; Gene 
Tools 
N/A 
LINE1 ASO: 
TGGCATTCTGTTCTTGTGGCTGTCT 
This paper; Gene 
Tools 
N/A 
siGenome siRNAs: custom and Smartpools (see Table 
S5) 
This paper; 
Dharmacon 
N/A 
LINE1 RNA smFISH probes Quasar 670 (see Table S5) This paper; Biosearch 
Technologies 
N/A 
Gapdh RNA smFISH probes Quasar 570 Biosearch 
Technologies 
Cat# SMF-3002-1 
Dux DNA FISH probes (see Table S5) This paper N/A 
LINE1 RNA ChIRP probes (see Table S5) This paper N/A 
Primers for qRT-PCR and ChIP-PCR (see Table S5) This paper N/A 
Recombinant DNA 
2C-GFP reporter (Ishiuchi et al., 2015) Addgene 69071 
CAG-smL1-ORFeus-GF-P (An et al., 2006) N/A 
pWA125-5’UTR-ORFeus-GF-P (Newkirk et al., 2017) N/A 
   
   
Software and Algorithms 
Trim galore! v0.4.0 Babraham 
Bioinformatics 
https://github.com/F
elixKrueger/TrimGal
ore 
Tophat2 v2.0.9 (Kim et al., 2013) https://ccb.jhu.edu/s
oftware/tophat/ 
Rsubread v1.22.3 (Liao et al., 2013) https://bioconductor.
org/packages/releas
e/bioc/html/Rsubrea
d.html 
R v3.3.0 /Bioconductor v3.3 R core team https://www.biocond
uctor.org/ 
Deseq2 v.1.12.3 (Love et al., 2014) http://bioconductor.o
rg/packages/DESeq
2/ 
GenePattern/GSEA Broad Institute http://www.broad.mit
.edu/gsea/ 
StarSearch (Raj et al., 2008) http://rajlab.seas.up
enn.edu/StarSearch/
launch.html 
FlowJo 10.3 FlowJo LLC  https://www.flowjo.c
om/ 
 Prism 7 GraphPad https://www.graphpa
d.com/scientific-
software/prism/ 
Fiji (Fiji Is Just ImageJ) ImageJ https://fiji.sc/ 
Other 
   
 
Percharde et al. Figure 1
Li
ne
1 
R
N
A
 fo
ci
 / 
ce
ll
-100
0
100
200
300
400 ****
LI
N
E
1 
R
N
A
 fo
ci
/c
el
l
  RC ASO      LINE1 ASO 0
50
100
150
***AP
-p
os
iti
ve
 c
ol
on
ie
s
RC ASO
LINE1 ASO
A B
LI
NE
1 
AS
O
RC
 A
SO
+RNase
LINE1
-RNAse
Day 0 
Nucleofect  ES cells
 with ASOs
Day 1 Day 2
Colony formation
assays
qRT-PCR
RNA-seq
RNA-FISH
ORF2ORF15'UTR
LINE1 ASO
siRNA1
siRNA2
3'UTR
ChIP
A(n)LINE1 mRNA
LINE1 LINE1Gapdh
LINE1
DAPI
RC ASO
LINE1 ASO
D
(n=59) (n=59)
LINE1 DAPI
2-
ce
ll 
em
br
yo
s
C
DAPI
DAPI
Bl
as
to
cy
st
s
E F
LINE1
LINE1
Figure Click here to download Figure rFigure1c.pdf 
A B C
Log10 mean expression
-2 0 2
Row Z-Score
RC ASO LINE1 ASO
Zs
ca
n4
Du
b1
Gm
43
40
Gm
20
22
Tc
stv
1
Tc
stv
3
0
1
2
3
4
10
20
30
40
50
60 RC ASO
LINE1 ASO
F
I
E
G
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
si
on
Percharde et al. Figure 2
[1-100]
Dub1
Zscan4d
[1-500]
MERVL-int
MT2_Mm
ORR1A3-int
LSU-rRNA_Hsa
SSU-rRNA_Hsa
-2
-1
0
1
2
3
0 2 4
Log10 mean expression
H
18
16
14
  
12
  
10
  
8
Distance to nearest MERVL
**
A
bs
ol
ut
e 
di
st
an
ce
 lo
g 2
(b
p)
2C/ASO
 intersect
ASO 
upregulated
All 
expressed 
P<0.01
MERVL-Pol MERVL-LTR
0
2
4
6
8
10
*
*
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
si
on
RC ASO
LINE1 ASO
D
Up with 
LINE1 ASO
             Down with
LINE1 ASO
**
**
NES: 2.75
FDR <0.0
Gm12794
Gm2022Zscan4d
Dub1
Tcstv1/3
*
Lo
g 2
 fo
ld
 c
ha
ng
e 
LI
N
E
1/
R
C
 A
S
O
Lo
g 2
 fo
ld
 c
ha
ng
e 
LI
N
E
1/
R
C
 A
S
O
Lo
g 2
 fo
ld
 c
ha
ng
e 
LI
N
E
1/
R
C
 A
S
O
RC 
LINE1 
RC 
LINE1 
2-cell genes
10
0
10
-5 0 5 10
PC1: 75% variance
P
C
2:
 2
2%
 v
ar
ia
nc
e
-10
RC ASO
LINE1 ASO
J
0 2 4 6 8 10
LINE1 ASO
RC ASO
% 2C-GFP positive
**
0
25
50
75
100
Oct4-/Chromo-
Oct4-/Chromo+
LINE1 ASO-induced
GFP+ cells
(n=46)
Oct4+/Chromo-
Oct4+/Chromo+
%
 c
el
ls
DAPI Oct4
2C-GFP Merge
K
RC ASO LINE1 ASO
Figure Click here to download Figure rFigure2b.pdf 
Percharde et al. Figure 3
R
el
at
iv
e 
m
R
N
A
 e
xp
re
ss
io
n
Dux 
RC ASO LINE1 ASO
0h: Nucleofect ESCs
with ASOs
RC ASO                     LINE1 ASO
6h: Transfect
siRNA
siControl siControlsiDux siDux
48h: Harvest RNA
A B
D
G
E
Log10 mean expression
MT2_Mm MERVL-int
IAPEz-int
LINE1 ASO
 siCon
RC ASO
 siCon
vs
Du
x
Du
b1
Tcs
tv3
Gm
434
0
ME
RV
L-L
TR
Sp
110
 0
5
10
15
RC ASO siControl
RC ASO siDux
LINE1 ASO siControl
LINE1 ASO siDux
IAP
Ez
Lo
g 2
 fo
ld
 c
ha
ng
e 
LI
N
E
1/
R
C
 A
S
O
Log10 mean expression
MT2_Mm
MERVL-int
IAPEz-int
RC ASO
 siCon
LINE1 ASO
 siDux
vs
F
Row Z Score
-2   -1   0   1    2
Dux
Gm13498
Inpp4b
Gm13109
0610040J01Rik
AU019990
Spz1
Gm4340
Ubtfl1
Gm13083
Zscan4b
Gm5662
Arg2
Zfp352
Cpb2
4933403O03Rik
Spesp1
Abcb5
Sp110
B020004J07Rik
AF067063
Ccl3
Gabra1
Lmx1a
Usp17l5
Tdpoz3
Zscan4e
Gm4858
Gm10696
Dub1
Gm13119
Dcc
Gm2016
Tmem92
Dub1a
Gm12794
Zscan4d
Zscan4f
Tcstv3
Gm5039
B020031M17Rik
Zscan4c
Gm8994
Gm2022
Gm8300
RC ASO
 siCon
LINE1 ASO
 siDux
RC ASO
 siDux
LINE1 ASO
 siCon
Top Dux-upregulated genes
*
75 Dux
-overlapping
2.5
2.0
1.5
1.0
0.5
0.0
-0.5
****
P < 2.2e-16
Lo
g 2
 F
C
 L
IN
E
1/
R
C
 A
S
O
Upregulation with LINE1 ASO
1521 non Dux
-overlapping
C
R
el
at
iv
e 
m
R
N
A
 e
xp
re
ss
io
n
0
10
20
30
40
Zsc
an4
Lo
g 2
 fo
ld
 c
ha
ng
e 
LI
N
E
1/
R
C
 A
S
O
Figure Click here to download Figure rFigure3b.pdf 
Percharde et al. Figure 4
**
D Fix Click-iT EU/HPG labelling
Flow
cytometry
Nucleofect
RC/LINE1 ASOs
45 min EU/HPG
48h RC ASO
LINE1 ASO
5
0
15
10
0
100
200
300
ns
RC
 A
SO
 si
Co
ntr
ol
LIN
E1
 A
SO
 si
Co
ntr
ol
LIN
E1
 A
SO
 si
Du
x
A
P
-p
os
iti
ve
 c
ol
on
ie
s
****
****
E
KEGG RIBOSOME KEGG RIBOSOME
Down with
LINE1 ASO
 siCon
Down with
LINE1 ASO
 siDux
UP with
LINE1 ASO
siCon
UP with
LINE1 ASO
siDux
NES = -3.38
FDR < 0.0
NES = -3.22
FDR < 0.0
+ siControl + siDux
RC ASO
A B C
LINE1 ASO
0
-0.1
-0.2
-0.3
-0.4
-0.5
-0.6
-0.7
-0.8E
nr
ic
hm
en
t s
co
re
0
-0.1
-0.2
-0.3
-0.4
-0.5
-0.6
-0.7E
nr
ic
hm
en
t s
co
re
R
N
A
 a
m
ou
nt
 (p
g/
ce
ll)
HG
N
or
m
al
iz
ed
 c
ou
nt
s
Nascent translation (HPG)
No HPG
RC ASO
LINE1 ASO
100
80
60
40
20
0
10-3 103 104 1050
0.0
0.5
1.0
1.5
R
el
at
iv
e 
H
P
G
 in
co
rp
or
at
io
n RC ASO
LINE1 ASO
0.0
0.5
1.0
1.5
N
or
m
al
iz
ed
 c
ou
nt
s
Nascent transcription (EU)
No EU
RC ASO
LINE1 ASO
100
80
60
40
20
0
10-3 103 104 1050
R
el
at
iv
e 
E
U
 in
co
rp
or
at
io
n
RC ASO
LINE1 ASO
F
Rp
l7
Rp
l3
pre
-rR
NA
rR
NA
-28
s
rR
NA
-18
s
0.0
0.5
1.0
1.5
R
el
at
iv
e 
ex
pr
es
si
on
RC ASO
LINE1 ASO
*
** * *
Figure Click here to download Figure rFigure4c.pdf 
APercharde et al. Figure 5
siControl
siYY1-1
siYY1-2
siDicer
siNcl
si
si
si
si
B
pr
e-r
RN
A
L1
Md
_A
L1
Md
_T
f
L1
Md
_G
f
L1
 O
rf2
Si
ne
B2 U1
0
2
4
6
8
10
R
el
at
iv
e 
R
IP
 e
nr
ic
hm
en
t
Ncl IP
IgG IP
LINE1 ChIRP
LINE1 ChIRP +RNase
Malat1 ChIRP
Int
-ch
r11
Rp
l3-
TS
S
Du
x-u
ps
tre
am
Du
x-c
od
ing
rD
NA
 5'
-E
TS
rD
NA
-28
S
0.0
0.5
1.0
1.5
**
*
**
nsns ns
D
N
A
 C
hI
R
P
 %
 in
pu
t
YY
1
Di
ce
r
Nc
l
Du
x
Tc
stv
3
Gm
43
40
Du
b1
R
el
at
iv
e 
m
R
N
A
 e
xp
re
ss
io
n siControlsiYY1-1
siDicer
siNcl
siYY1-2
C
0.5
1.0
1.5
2.0
2.5
5
10
15
20
KD validation
Dux and 2C gene expression
F
−2
0
2
4
−2 0 2 4
Dux
Zscan4
Dub1
Tcstv3
Gm8300Gm2022
Gapdh
Nanog
Sp110
Dub1a
log2FC LINE1/RC ASO
lo
g 2
FC
 s
iN
cl
/s
iC
on
tro
l
σ = 0.6
Zs
ca
n4
D0
100
200
300
****
A
P
-p
os
iti
ve
 c
ol
on
ie
s
siControl
siNcl
H
0
5
10
15
siControl
siNcl
**
G
siControl
siNcl
R
N
A
 a
m
ou
nt
 (p
g/
ce
ll)
D
E
43 Dux
-overlapping
3
2
1
0
-1
-2
****
P < 2.2e-16
Lo
g 2
 F
C
 s
iN
cl
/s
iC
on
tro
l
Upregulation with Ncl knockdown
3303 non Dux
-overlapping
PC1: 89% variance
P
C
2:
 8
%
 v
ar
ia
nc
e
siControl
siNcl
10
0
-10
-10            0             10
Figure Click here to download Figure rFigure5d.pdf 
APercharde et al. Figure 6
siControl
siYY1-1
siYY1-2
siDicer
siNcl
si
si
si
si
B
IB: NclIB: Kap1
IP: 
Inp
ut
αK
ap
1
αN
cl
Be
ad
s
Inp
ut
αN
cl
Be
ad
s
αK
ap
1IP: 
RC ASO Ncl IP
LINE1 ASO Ncl IP
RC ASO Kap1 IP
RC ASO IgG IP
LINE1 ASO Kap1 IP
LINE1 ASO IgG IP
Rp
l3-
TS
S
Du
x-c
od
ing
Du
x-T
SS
0
5
10
15
20
25
Rp
l3-
TS
S
0
2
4
6
8
10
**ns
*
C
hI
P
 e
nr
ic
hm
en
t
C
hI
P
 e
nr
ic
hm
en
t
ns
* *
Ncl IP Kap1 IP
Du
x-c
od
ing
Du
x-T
SS
5'ETS 18S 28S IGS
>>>>>>>>>>>>>>>>>>>
Dux-TSS Dux-coding
Dux repeat unit rDNA repeat unit
Rp
l3-
TS
S
rD
NA
-28
S
rD
NA
-5'
ET
S
0
100
200
300
IA
PE
z
0
10
20
30
40
50
#C
hI
P
 e
nr
ic
hm
en
t
C
hI
P
 e
nr
ic
hm
en
t
ns
*
ns
**
Ncl IP Kap1 IP
ns
Rp
l3-
TS
S
rD
NA
-28
S
rD
NA
-5'
ET
S
Du
x
Zs
ca
n4
Du
b1
ME
RV
L-L
TR
IA
PE
z
0
20
40
60
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
si
on ** *
****
**
**
0.0
0.5
1.0
1.5
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
si
on Kap1 f/f
Kap1 Δ/Δ
****
Kap1
Kap1 f/f
Kap1 Δ/Δ
C
D
F
G
siControl siNcl siKap1
0 5 10 15 20
% 2C-GFP positive
*
*
siCon
siNcl
siKap1
E
LI
N
E
1 
R
N
A
ES cells 2C-like cells
LI
N
E
1 
R
N
A
 fo
ci
 p
er
 n
uc
le
us
ES cells  
(n=97)
2C-like cells
(n=129)
0
50
100
150
200
250 ****
H ES cell
2C-like cell
N
cl
/D
ux
N
cl
/D
ux
LI
N
E
1/
D
A
P
I
0
20
40
60
80
100
%
 D
ux
 lo
ci
Nucleolus LaminaNucleoplasm
χ2=4.1e-25
ES cells  
(n=246)
2C-like cells
(n=138)
****
Figure Click here to download Figure rFigure6.pdf 
Percharde et al. Figure 7
siControl
siYY1-1
siYY1-2
siDicer
siNcl
si
si
si
si
D
Develop to 2C
Progressed beyond 2C
0
50
100
%
 e
m
br
yo
s
P = 5.0e-8
P = 7.3e-291
Un
inje
cte
d 
Co
ntr
ol A
SO
 0.
5X
 
Co
ntr
ol A
SO
 1X
 
LIN
E1
 AS
O 0
.5X
 
LIN
E1
 AS
O 1
X 
0
10
20
30 MERVL-LTR RC 4-cell (9)
RC 4-cell (7)
RC 5-8-cell (11)
RC 5-8-cell (11)
LINE1 ASO 4-cell (9)
LINE1 ASO 4-cell (7)
LINE1 ASO 4-cell (12)
m
R
N
A 
ex
pr
es
si
on
Control ASO LINE1 ASO 
0
5
10
15
20
25 ***
C
yt
op
la
sm
ic
/n
uc
le
ar
 
18
S
 F
IS
H
 ra
tio
(n=8) (n=13)
Control ASO LINE1 ASO
18S RNA 18S RNA
DAPIDAPI
ASO 
microinjection
late2C
qRT-PCR/
RNA-FISH
Blastocyst
Embryo 
progression
ZygoteA Uninjected 1
Control ASO 1
RC ASO 1
LINE1 ASO 1
Uninjected 2
Control ASO 2
LINE1 ASO 2
0
5
10
15
20
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
si
on
Dux Zscan4 Eif1a
C
E
-1.0
-0.5
0.0
0.5
1.0
Lo
g 2
FC
 L
IN
E
1/
R
C
 A
S
O
Zygote early2C 4C
RNA-seq analysis
ASO 
microinjection
G
>>>>>>>>>>>>>>>>>>>
Dux repeat unit
rRNA synthesis
Hypertranscription
Efficient self-renewal
Dux repression
2C/MERVL silencing
2-cell exit
Nucleolin
Kap1
AA
AA
A
LINE1
rDNA repeat unit
?
LINE1Dux/MERVL
2C state ICM/ES state 
2-cell Blastocyst
L
Developed to≤ 4C
Progressed beyond 4C
Un
inje
cte
d 
RC
 AS
O
LIN
E1
 AS
O
0
50
100
%
 e
m
br
yo
s
P = 6.5e-49
K
B
****
Cluster 4
(n=1223)
Cluster 1
(n=2454)
ZGA
(n=204)
All
(n=17709)
R
el
. F
P
K
M
MII
 oo
cyt
e
Zyg
ote
Ea
rly 
2C 2C 4C 8C ICM
120
100
80
60
40
20
0
600
500
400
300
200
100
0
R
el
. F
P
K
M
Cluster 4: early 2C up
Cluster 1: 4C up
ZGA-associated250
200
150
100
50
0
MII
 oo
cyt
e
Zyg
ote
Ea
rly 
2C 2C 4C 8C ICM
F
n=
25
n=
47
n=
34
J
n=
23
n=
23
n=
20
n=
52 n=
42
****
****
4C embryo RNA-seq LINE1/RC ASO
H
ASO 
microinjection
late2C 4C
Collect
qRT-PCR
Blastocyst
Embryo 
progression
I
2C RC ASO
2C LINE1 ASO
4C RC ASO
4C LINE1 ASO
5
10
15 Dux
early 2C 4C
2
4
6
8
10 Zscan4d
Lo
g 2
 n
or
m
al
iz
ed
 re
ad
s
Lo
g 2
 n
or
m
al
iz
ed
 re
ad
s
early 2C 4C* *
>>>>>>>>>>>>>>>>>>>
?
LINE1
Figure Click here to download Figure rFigure7-v3.pdf 
BPercharde et al. Figure S1
siControl
siLine1 #1
siLine1 #4
4d
Du
b1
-2
Gm
43
40
Gm
20
22
Tc
stv
1
Tc
stv
3
no
rm
al
is
ed
 m
R
N
A
 e
xp
re
ss
io
n
C
A
siCon siLINE1 #1
100
200
300
FI
SH
 fo
ci
/c
el
l
Line1 Orf2 FISH
****
****
R
N
A 
FI
S
H
 fo
ci
 p
er
ce
ll
m2
02
2
Tc
stv
1
Tc
stv
3
siLINE1 #2
(n=117) (n=117) (n=73)
Lissamine
10-3  0 103  104  105
Lissamine
10-3  0 103  104  105
Lissamine
10-3  0 103  104  105
S
S
C
-A
250K
200K
150K
100K
50K
0
S
S
C
-A
250K
200K
150K
100K
50K
0
S
S
C
-A
250K
200K
150K
100K
50K
0
No ASO RC ASO LINE1 ASO
ASO-positive
0.04%
ASO-positive
89.5%
ASO-positive
70.3%
D
0
1
2
3
4
5
**
RC ASO LINE1 ASO
H
0
20
40
60
80
100
120
G0/G1 S G2/M
**
** χ2 = 0.00276
E
0
20
40
60
N
um
be
r o
f A
P+
 c
ol
on
ie
s siControl
siLine1 #1
siLine1 #2
A
P
-p
os
iti
ve
 c
ol
on
ie
s
**
***
FBS/LIF
siControl
siLINE1 #1
siLINE1 #2
0 24 48 72 96 120
0
50
100
150
Hours in culture after NF
N
um
be
r o
f c
el
ls
 /m
illi
on
RC ASO
LINE1 ASO
NF
* ***
***
***
***
RC ASO LINE1 ASO
G
%
 c
el
ls
RC ASO LINE1 ASO
Nanog
Oct4
Gapdh
RC
 A
SO
RC
 A
SO
LI
NE
1 A
SO
LI
NE
1 A
SO
%
 S
yt
ox
-p
os
iti
ve
NanogOct4 DAPI
RC
 A
SO
LI
NE
1 
AS
O
F
Orf1p DAPI Merge
Supplemental Figure Click here to download Supplemental Figure rFigureS1.pdf 
EPercharde et al. Figure S2
siControl
siLine1 #1
siLine1 #4
4d
Du
b1
-2
Gm
43
40
Gm
20
22
Tc
stv
1
Tc
stv
3
Zs
ca
n4
d
Du
b1
-2
Gm
43
40
Gm
20
22
Tc
stv
1
Tc
stv
0
5
10
15
20
no
rm
al
is
ed
 m
R
N
A
 e
xp
re
ss
io
n
0
5
10
15
20
no
rm
al
is
ed
 m
R
N
A
 e
xp
re
ss
io
n
D
Zs
ca
n4
dD
D
Du
b1
-2
Gm
43
40
Gm
20
22
Tc
stv
1
Tc
stv
3
0
5
10
15
20
no
rm
al
is
ed
 m
R
N
A
 e
xp
re
ss
io
n
n.d.
A B
R
el
at
iv
e 
m
R
N
A
 e
xp
re
ss
io
n
R
el
at
iv
e 
m
R
N
A
 e
xp
re
ss
io
n
140145
32
Up with 
LINE1 ASO
Up in
Zscan4+/MERVL+ 
cells
Eckersley-Maslin 2016
P <2.2e-16
Ga
ta6
Br
ac
yh
ury Fg
f5
Ot
x2
0
1
2
3
4
5
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
si
on
RC ASO
LINE1 ASO
C
n.s. n.s.
n.s.
*
I
Zsc
an4
0
50
100
150
200
250
0
20
40
60
80
100
LINE1 CAG-ORFeus
0
50
100
150
200
250
LINE1 5'UTR-ORFeus
Du
b1
Zs
ca
n4
Tc
stv
3
Gm
43
40
Sp
11
0
ME
RV
L-L
TR
IA
PE
z
0
2
4
6
8
10 No treatment
d4T
TDF
G
FP
 p
os
iti
ve
 c
el
ls No treatment
d4T
TDF
No treatment
d4T
TDF
A
P
-p
os
iti
ve
 c
ol
on
ie
s
F
G H
ORF2ORF1
GFP
GFP
retrotransposition
G
FP
 p
os
iti
ve
 c
el
ls
LINE1 5'UTR 
or CAG promoter
siLINE1 #1
siLINE1 #2
siControl
0.999 1
Correlation
Log2 fold change LINE1/RC ASO
-2 -1 0 1 2
Pou5f1
Sox2
Nanog
Esrrb
Zfp42
Dppa3
Sox17
Gata6
Gata4
FoxA2
Brachyury
Mixl1
Cd34
Shh
Fgf5
Pax6
Cxcl12
Otx2
Sox1
Endo
Meso
Ecto
Plurip
2.5
2
1.5
1
0.5
0
-0.5
2C
 g
en
es
L1
-c
on
ta
ini
ng
L1
 <
10
kb
L1
 <
10
0k
b
L1
 <
1M
b
L1
 >
1M
b
n=106
n=520 n=201 n=1882 n=9421 n=4977
P < 2.2e-16
P = 5.2e-6
Lo
g 2
FC
 L
IN
E
1/
R
C
 A
S
O
RC ASO 1
RC ASO 3
RC ASO 2
LINE1 ASO 3
LINE1 ASO 2
LINE1 ASO 1
Macfarlan 2012
118149
28
Up with
LINE1 ASO
Up in
2C-like cells
Ishiuchi 2015
140
40
Up with
LINE1 ASO
Up with 
CAF-1 depletion
137
P <2.2e-16 P <2.2e-16
Du
b1
Gm
434
0
Gm
202
2
Tcs
tv1
Tcs
tv3
***
*** ***
***
***
***
***
***
***
0
2
4
6
ME
RV
L-L
TR
ME
RV
L-P
ol
ME
RV
K
IA
P-
Ez
Du
b1
Zs
ca
n4
Tc
stv
3
Gm
43
40
J K
Du
x
Du
b1
Zs
ca
n4
Gm
43
40
ME
RV
L-L
TR
0.1
1
10
100
1000
10000 2C GFP -ve
2C GFP +ve
R
el
at
iv
e 
m
R
N
A
 e
xp
re
ss
io
n
R
el
at
iv
e 
m
R
N
A
 e
xp
re
ss
io
n
RC ASO
LINE1 ASO
Supplemental Figure Click here to download Supplemental Figure rFigureS2.pdf 
Percharde et al. Figure S3
A
0
10000
20000
30000
MERVL-int
0
1000
2000
3000
4000
MT2_Mm
B C
C
ou
nt
s 
pe
r m
ill
io
n
C
ou
nt
s 
pe
r m
ill
io
n
RC ASO siControl
RC ASO siDux
LINE1 ASO siControl
LINE1 ASO siDux
Lo
g 2
FC
 L
IN
E
1/
R
C
 A
S
O
2C/MERVL repressors
Ka
p1
Zfp
80
9
Ls
d1
RY
BP
Eh
mt
2
Zfp
42
Ez
h1
Ez
h2
Su
v3
9h
1
Su
v3
9h
2
Mb
d3
-1
0
1
2
2.5
2.0
1.5
1.0
0.5
0.0
-0.5
***
P < 4.7e-6
Lo
g 2
 F
C
 L
IN
E
1/
R
C
 A
S
O
+ siControl        + siDux
Top Dux targets
E
Du
x
Zs
ca
n4
Du
b1
Gm
43
40
Tc
stv
3
ME
RV
L-L
TR
IA
PE
z
0
5
10
15
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
si
on
RC ASO
LINE1 ASO
0
50
100
150
200
N
um
be
r A
P+
 C
ol
on
ie
s
***
RC ASO
LINE1 ASO
N2B27/2i + LIF ES culture conditions
D
RC ASO siControl
LINE1 ASO siControl LINE1 ASO siDux
RC ASO siDux
−10
−5
0
5
10
−10 −5 0 5 10
PC1: 53% variance
P
C
2:
 2
3%
 v
ar
ia
nc
e
F
HG I
Rp
l3-
Ts
s
Int
-ch
r11
Du
x-T
SS
Du
x-c
od
ing
ME
RV
L-L
TR
Me
rvl
-P
ol
Zs
ca
n4
Ho
xA
11
0
10
20
30
40
50 RC ASO K9me2
LINE1 ASO K9me2
RC ASO IgG
LINE1 ASO IgG
Rp
l3-
Ts
s
Int
-ch
r11
Du
x-T
SS
ME
RV
L-L
TR
Me
rvl
-P
ol
Zs
ca
n4
Ho
xA
11
0
20
40
60
80 RC ASO K9me3LINE1 ASO K9me3
RC ASO IgG
LINE1 ASO IgG
Rp
l3-
Ts
s
Int
-ch
r11
Du
x-T
SS
ME
RV
L-L
TR
Me
rvl
-P
ol
Zs
ca
n4
Ho
xA
11
0
2
4
6
8
10 RC ASO K27me3
LINE1 ASO K27me3
RC ASO IgG
LINE1 ASO IgG
Du
x-c
od
ing
Du
x-c
od
ing
%
 in
pu
t
%
 in
pu
t
%
 in
pu
t
Supplemental Figure Click here to download Supplemental Figure rFigureS3.pdf 
Percharde et al. Figure S4
0
20
40
60
N
um
be
r o
f A
P+
 c
ol
on
ie
s
KSR
0
20
40
60
N
um
be
r o
f A
P+
 c
ol
on
ie
s siControl
siLine1 #1
siLine1 #2
FBS
Zs
ca
n4
d
Du
b1
-2
Gm
43
40
Gm
20
22
Tc
stv
1
Tc
stv
3
0
5
10
15
20
no
rm
al
is
ed
 m
R
N
A
 e
xp
re
ss
io
n
RC ASO         LINE1 ASO
Rpl/Rps genes
-2 0 2
Row Z Score
Up with
LINE1 ASO
Down with
LINE1 ASO
Zs
ca
n4
Du
b1
Tc
stv
1
Tc
stv
3
ME
RV
L-L
TR
0
5
10
15
RC ASO day 1
LINE1 ASO day 1
RC ASO day 2
LINE1 ASO day 2
#
**
***
N
or
m
al
iz
ed
 m
R
N
A
 e
xp
re
ss
io
n
A B
0
50
100
150
***
A
P
-p
os
iti
ve
 c
ol
on
ie
s
C
D
NES = -3.29
FDR <0.0
KEGG RIBOSOME
Up with
LINE1 ASO
Down with
LINE1 ASO
p53-/- ES cells p53-/- ES cellsP53 TARGETS
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
NES = 2.12
FDR <0.0
RC ASO LINE1 ASO
E
0
-0.1
-0.2
-0.3
-0.4
-0.5
-0.6
-0.7
-0.8
E
nr
ic
hm
en
t s
co
re
E
nr
ic
hm
en
t s
co
re
**
***
0
-0.1
-0.2
-0.3
-0.4
-0.5
-0.6
-0.7E
nr
ic
hm
en
t s
co
re
Up with
LINE1 ASO
Down with
LINE1 ASO
NES = -3.31
FDR <0.0
REACTOME_TRANSLATION
F
Rpl/Rps genes
Rpl/Rps genes
(n=86)
All genes
(n=18039)
0.4
0.2
0
-0.2
-0.4
Lo
g 2
 F
C
 L
IN
E
1/
R
C
 A
S
O
***
P < 2.2e-16
0.0
0.5
1.0
1.5
0 24 48 72
0
2
4
6
8h CX-5461
treatment
0
50
100
150
200
A
P
-p
os
iti
ve
 c
ol
on
ie
s
N
as
ce
nt
 R
N
A
 e
xp
re
ss
io
n
N
um
be
r o
f c
el
ls
 /m
ill
io
n
****
G H I
0μM CX 8h
1μM CX 8h
0μM CX 8h
1μM CX 8h
0μM CX 8h
1μM CX 8h
Hours in cultureRp
l7
Pre
-rp
l3
Pre
-rR
NA
rRN
A-2
8S
rRN
A-1
8S
*** ** *
**
Supplemental Figure Click here to download Supplemental Figure rFigureS4.pdf 
APercharde et al. Figure S5
siControl
siYY1-1
siYY1-2
siDicer
siNcl
si
si
si
si
pre
-rR
NA
L1
Md
_A
L1
Md
_T
f
L1
Md
_G
f
L1
 O
rf2
Sin
eB
2 U1
Ma
lat
1
0
10000
20000
30000
40000
50000
60000
70000
80000
E
xp
re
ss
io
n 
re
la
tiv
e 
to
 G
ap
dh
CB
Hp
1a
Hp
1b Du
x
Du
b1
Zs
ca
n4
Tc
stv
3
Gm
43
40
Sp
11
0
ME
RV
L-L
TR
IA
PE
z
0.0
1.0
2.5
5
10
15
20
25
R
el
at
iv
e 
m
R
N
A
 e
xp
re
ss
io
n
siControl
siHp1a
siHp1b
siNcl
KD validation
Dux and 2C gene expression
Nucleolin
Actin
siC
on
tro
l
siN
cl
D
0.0
0.5
1.0
1.5
siControl
siNcl
H
J
0
10000
20000
30000
40000
MERVL-int
0
1000
2000
3000
4000
MT2_Mm
C
ou
nt
s 
pe
r m
ill
io
n
C
ou
nt
s 
pe
r m
ill
io
n
E
Ncl
K
KEGG RIBOSOME
Down with
siNcl
UP with
siNcl
NES = -2.60
FDR < 0.0
Ma
lat
1
Ne
at1
0
20
40
60 *
**D
N
A
 C
hI
R
P
 %
 in
pu
t
Ac
tin
Ga
pd
h
L1
 O
rf2
L1
Md
_A
L1
Md
_T
f
L1
Md
_G
f
Ma
lat
1
0
5
10
15
20
25
R
N
A 
C
hI
R
P 
%
 in
pu
t
LINE1 ChIRP
Malat1 ChIRP
LINE1 ChIRP
LINE1 ChIRP +RNase
Malat1 ChIRP
F
L
0
-0.1
-0.2
-0.3
-0.4
-0.5
-0.6
-0.7E
nr
ic
hm
en
t s
co
re
0
50
100
150
200
****
**
*
Nc
l
Du
x
Zs
ca
n4
Tc
stv
3
Gm
43
40
ME
RV
L-L
TR
0
2
4
6
8
10 siControl
siNcl
siNcl + siDux
R
el
at
iv
e 
m
R
N
A
 e
xp
re
ss
io
n
R
el
at
iv
e 
m
R
N
A
 e
xp
re
ss
io
n
A
P
-p
os
iti
ve
 c
ol
on
ie
s
siControl
siNcl
siNcl + siDux
rR
NA
L1
Md
_A
L1
Md
_T
f
L1
Md
_G
f
L1
 O
rf2 U1
0.0
0.5
1.0
1.5
R
IP
 %
 In
pu
t
Ncl IP -DNase
IgG IP -DNase
Ncl IP +DNase
IgG IP +DNase
pos
LINE1
neg
L1
_O
rf2
L1
Md
_A
L1
Md
_G
f
L1
Md
_T
f
0
2
4
6
D
N
A-
C
hI
R
P 
%
 In
pu
t
LINE1 ChIRP
LINE1 ChIRP +RNase
Malat1 ChIRP
***
**
***
**
siC
on
tro
l
siN
cl
siC
on
tro
l
siN
cl
G
I
Supplemental Figure Click here to download Supplemental Figure rFigureS5b.pdf 
APercharde et al. Figure S6
siControl
siYY1-1
siYY1-2
siDicer
siNcl
si
si
si
si
C
B
D
m
R
N
A
 e
xp
re
ss
io
n
m
R
N
A
 e
xp
re
ss
io
n
F
0
1
2
3
4
Ncl
RC ASO
LINE1 ASO
n.s.
0
1
2
3
4
Ncl
siControl
siLINE1 #1
siLINE1 #2
n.s.
E
HG
Rp
l7
Pr
e-R
pl3
pre
-rR
NA
rR
NA
-28
s
0
1
2
3
siControl
siNcl
N
as
ce
nt
 R
N
A
 e
xp
re
ss
io
n
Rp
l7
Rp
l3
pre
-rR
NA
rR
NA
-28
s
0
1
2
3
RC ASO
LINE1 ASO
N
as
ce
nt
 R
N
A
 e
xp
re
ss
io
n
Rp
l7
pre
-R
pl3
pre
-rR
NA
rR
NA
-28
s
0
1
2
3
Kap1 f/f
Kap1 Δ/Δ
N
as
ce
nt
 R
N
A
 e
xp
re
ss
io
n
2C
-G
FP
D
A
P
I
IB
: K
ap
1
IP: Input αKap1 αNucleolin IgG
LINE1RC LINE1RC LINE1RC LINE1RC
Kap1
Nucleolin
Gapdh
LI
NE
1 
AS
O
RC
 A
SO
ASO:
2C
-G
FP
O
ct
4ES cell 
(n=159)
0
20
40
60
80
100
120 No nucleoli
1 nucleolus
2 nucleoli
3 nucleoli
4 nucleoli
χ2 < 0.0001
****
%
 c
el
ls
2C cell 
(n=109)
−4
0
4
8
−2 0 2 4
log2FC LINE1/RC ASO
lo
g 2
FC
 K
ap
1 
K
O
/W
t
σ = 0.34Kap1
Lamina (L) Nucleolus (N) Nucleoplasm (P)
I
N
uc
le
ol
in
/D
ux
J
N
uc
le
ol
in
/D
ux
2C
-G
FP
2xP
L N
K
0
20
40
60
80
100
1+ nucleoplasmic Dux
0 nucleoplasmic Dux
%
 c
el
ls
ES cell 
(n=134)
2C cell 
(n=75)
χ2=1.5e-25
****
N
uc
le
ol
in
/K
ap
1
N
uc
le
ol
in
/D
A
P
I
Supplemental Figure Click here to download Supplemental Figure rFigureS6.pdf 
Percharde et al. Figure S7
A
0
50
100
Failed to develop to blastocyst
Developed to blastocyst
%
 e
m
br
yo
s
P = 1.1e-44
P = 1.7e-236
****
RC
 AS
O
(n=8)
LIN
E1
 AS
O
(n=14)
P
C
2:
 1
%
 v
ar
ia
nc
e
PC1: 96% variance
10
0
-10
-50 0 50
2C RC ASO
2C LINE1 ASO
4C RC ASO
4C LINE1 ASO
B
E
2C RC ASO
2C LINE1 ASO
4C RC ASO
4C LINE1 ASO
6
8
10
12
Ddit4l
****
4
6
8
10
12
Dub1a
Lo
g 2
 n
or
m
al
iz
ed
 re
ad
s
Lo
g 2
 n
or
m
al
iz
ed
 re
ad
s
early 2C
4C *
early 2C
4C
G
KEGG Ribosome
NES = -2.89
FDR < 0.0
0
-0.1
-0.2
-0.3
-0.4
-0.5
-0.6
-0.7E
nr
ic
hm
en
t s
co
re
Down with 
LINE1 KD
UP with
LINE1 KD
Uni
njec
ted
RC
 AS
O
LIN
E1 
ASO
0
50
100
Failed to develop to blastocyst
Developed to blastocyst
n=
25
n=
47
n=
34
%
 e
m
br
yo
s
P = 1.2e-100
H
I
Un
inje
cte
d
Co
ntr
ol A
SO
 0.
5X
Co
ntr
ol A
SO
 1X
LIN
E1
 AS
O 0
.5X
LIN
E1
 AS
O 1
X
n=
23
n=
23
n=
20
n=
52
n=
42
D
0
50
100
P = 1.01e-27
DMSO 1μM CX-5461
%
 e
m
br
yo
s
n=
39
n=
47
Failed to develop to blastocyst
Developed to blastocyst
R
el
at
iv
e 
in
te
ns
ity
C
R
C
 A
S
O
LI
N
E
1 
A
S
O
H3K9me2H3K9me3DAPI
N
o 
D
N
A
se
R
C
 A
S
O
LI
N
E
1 
A
S
O
TUNELHoechst
FP
K
M
, r
el
. t
o 
zy
go
te
MI
I_o
oc
yte
zy
go
te
ea
rly
 2-
ce
ll
2-c
ell
4-c
ell
8-c
ell IC
M
0
1
2
3
MI
I_o
oc
yte
zy
go
te
ea
rly
 2-
ce
ll
2-c
ell
4-c
ell
8-c
ell IC
M
0
5
10
15
20
Ncl
Kap1
0.00
0.05
0.10
0.15
m
R
N
A 
ex
pr
es
si
on
Dux
nd nd
0
5
10
15 Zscan4
nd nd0.00
0.01
0.02
0.03
0.04
0.05 Ddit4l
RC 4-cell (9)
RC 5-8-cell (11)
RC 5-8-cell (11)
LINE1 ASO 4-cell (9)
LINE1 ASO 4-cell (12)
0.5
1.0
1.5
2.0
0.5
1.0
1.5
2.0 ****
RC
 AS
O
(n=8)
LIN
E1
 AS
O
(n=14)
R
el
at
iv
e 
in
te
ns
ity
H3K9me2 H3K9me3
MI
I o
ocy
te
Zy
go
te
Ea
rly 
2C
2C 4C 8C ICM
1
2
3
5
6
F
4 (Dux)
(n=14)(n=13)0.0
0.5
1.0
1.5
2.0
2.5
R
el
at
iv
e 
TU
N
EL
 In
te
ns
ity **
RC
 AS
O
LIN
E1
 AS
O
J
K
FP
K
M
, r
el
. t
o 
zy
go
te
Supplemental Figure Click here to download Supplemental Figure rFigureS7b.pdf 
  
Table S1
Click here to access/download
Supplemental Videos and Spreadsheets
TableS1.xlsx
  
Table S2
Click here to access/download
Supplemental Videos and Spreadsheets
TableS2.xlsx
  
Table S3
Click here to access/download
Supplemental Videos and Spreadsheets
TableS3.xlsx
  
Table S4
Click here to access/download
Supplemental Videos and Spreadsheets
TableS4.xlsx
  
Table S5
Click here to access/download
Supplemental Videos and Spreadsheets
TableS5.xlsx
